Common pathological mechanisms and therapeutic strategies in primary Sjogren’s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy

Autoimmune diseases are characterized by their involvement of multiple organ systems and the presence of overlapping clinical manifestations among distinct disease entities. Both primary Sjogren’s syndrome (pSS) and primary biliary cholangitis (PBC) are chronic inflammatory disorders driven by immune-mediated injury to glandular or ductal epithelial cells. Due to shared genetic susceptibility, epidemiological patterns, and pathophysiological mechanisms, these two diseases frequently coexist in clinical practices and demonstrate a common tissue immune microenvironment. Recent advances have greatly enhanced the understanding of pSS and PBC pathogenesis, particularly regarding autoantibody profiles and pro-inflammatory cytokine expression in serum, as well as the functional activity of immune cells within affected tissues. These insights provide new perspectives and potential avenues for the development of targeted therapeutic strategies. This review examines the associations between pSS and PBC, explores the shared immunological pathways involved in disease onset and progression, and summarizes common therapeutic targets within the context of clinical treatment. The goal is to provide a comprehensive perspective that may guide future research and inform improved diagnostic and therapeutic strategies for both conditions.

1 Introduction

pSS and PBC are two prevalent autoimmune diseases characterized by immune-mediated damage to epithelial cells in exocrine glands or bile ducts, both classified as chronic immune-mediated epithelitis (1, 2). pSS is defined by focal lymphocytic infiltration of exocrine glands leading to structural and functional impairment of the affected tissues, and is frequently accompanied by multisystem and multiorgan involvement (1). PBC is a disease in which lymphocytic infiltration triggers inflammatory destruction of the intrahepatic portal tracts and small bile ducts, resulting in progressive hepatic fibrosis and intrahepatic cholestasis (3). Both pSS and PBC share key immunopathological features, particularly immune cell infiltration within glands or ducts, and exhibit similar pathogenic mechanisms as well as overlapping clinical manifestations.

Clinically, pSS and PBC frequently coexist within the same individual, and epidemiological studies have consistently demonstrated a relatively high comorbidity rate between these two diseases. It has been reported that approximately 19%-31% of PBC patients may be comorbid with pSS (4). Furthermore, xerostomia is observed in 43.1% of PBC patients, and histopathological examination of minor salivary glands (MSGs) in the early stages of PBC often reveals lesions that closely resemble those seen in pSS, subsequently leading to dysfunction of both lacrimal and MSGs (5, 6). In pSS, the liver represents one of the earliest extra-glandular organs to be affected. Even in pSS patients without a prior history of liver disease, clinical manifestations such as hepatomegaly and abnormal liver function tests are frequently observed, and liver biopsies in most pSS patients diagnosed with PBC reveal histological features characteristic of early-stage (Stage I) PBC (6, 7). In the absence of antimitochondrial antibody (AMA) detection and liver histological evaluation, PBC may be underdiagnosed in pSS patients, particularly in those who lack overt clinical signs of cholestasis. Therefore, the true prevalence of PBC among patients with pSS may be significantly underestimated in clinical settings.

Over the past several decades, the frequent comorbidity of pSS and PBC has garnered considerable clinical attention; however, the underlying mechanisms driving this association remain poorly understood. In recent years, a growing body of research has been dedicated to elucidating the immunopathological connections between the two diseases. This review focuses on the similarity of pSS and PBC, explores their shared pathogenic mechanisms, and systematically summarizes the overlapping therapeutic strategies observed in clinical practice. These insights may offer novel conceptual approaches for developing therapeutic strategies in pSS and PBC.

2 Risk factor similarities

Genetic factors play a critical role in the pathogenesis of both pSS and PBC. A Mendelian randomization analysis of the genetic data from patients with pSS and PBC suggests that these two diseases may share common genetic susceptibility loci. The onset of pSS has been associated with an increased risk of developing PBC; moreover, patients with pSS combined with autoimmune liver disease exhibit more severe disease progression and a higher mortality rate (8). Familial aggregation of pSS and PBC has also been documented. Relatives of affected individuals show a higher incidence of these diseases and are frequently affected by other autoimmune or connective tissue disorders (9, 10). At the HLA locus, pSS and PBC patients exhibit similar genetic alterations, including both susceptibility and protective alleles associated with disease onset and progression (11, 12). Additionally, genetic variants outside the HLA region also contribute to disease susceptibility, particularly those involved in T cell activation; B cell development, activation, and migration; as well as in the expression of inflammation-related signaling molecules (13, 14). These genetic variations are summarized in Table 1 and represent key factors underlying the shared predisposition to pSS and PBC.

Table 1

Table 1. Similar HLA genetic locus alterations.

Females predominate among patients with pSS and PBC. Women’s T cells express more genes related to inflammatory and cytotoxic effector molecules compared to men’s, and several genes essential for maintaining immune tolerance are located on the X chromosome, suggesting that sex-related factors may play a critical role in disease etiology (21, 22). Liu K et al. have reported that the prevalence of pSS in women with triple X syndrome (47, XXX) is 2.9 times higher than in karyotypically normal women and 41 times higher than in males (23). Similarly, another retrospective study found that the incidence of SS in women with triple X syndrome is 2.3 times higher than in the general female population (24). Due to the unique epigenetic characteristics of the X chromosome, one X homolog undergoes inactivation in females to achieve equivalent levels of X-linked gene expression between sexes. This process, known as X-chromosome inactivation, has been proposed as a key contributor to the female predisposition to autoimmune diseases (25, 26). The frequency of X monosomy increases significantly with age in female PBC patients (27); X chromosome loss occurs more preferentially and frequently in peripheral blood mononuclear cells (PBMCs) of female PBC patients (28). A chromosome-wide association study further identified seven genes (TIMM17B, PQBP1, PIM2, SLC35A2, OTUD5, KCND1, and GRIPAP1) as potentially associated with PBC pathogenesis (29). Although X chromosome inactivation has not been extensively studied in SS, current evidence underscores the profound influence of the X chromosome on the development of both pSS and PBC.

In addition to X chromosome abnormalities and related gene expression, sex hormone levels are closely associated with the development of pSS and PBC. Both pSS and PBC predominantly affect perimenopausal and postmenopausal women, who typically exhibit reduced levels of estrogen and other hormones involved in its biosynthesis (30, 31). Since estrogen receptors are widely expressed on the surface of various immune cells, estrogen can modulate immune function by suppressing the production of pro-inflammatory cytokines from T helper type 1 (Th1) cells, stimulating anti-inflammatory cytokine secretion from Th2 cells, and regulating the balance between Th17 cells and regulatory T cells (Tregs). Consequently, dysregulated or diminished estrogen levels in perimenopausal women can enhance Th17 cell activation and impair the immunosuppressive function of Tregs, ultimately increasing susceptibility to pSS and PBC. Experimental studies using an ovariectomized murine model have demonstrated accelerated pSS progression and aggravated tissue damage; estrogen treatment significantly ameliorated inflammatory lesions in the submandibular glands (SG) of SS mice and reduced glandular lymphocyte infiltration (32). Similarly, female PBC mice displayed more severe upregulation of interferon (IFN) signaling and cholestasis compared to males (33). Moreover, the estrogen precursor dehydroepiandrosterone and its metabolites significantly reduce interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) production by cholangiocytes and hepatocytes in PBC patients, thereby modulating the biliary immune microenvironment and alleviating hepatic inflammation (31).

Environmental exposures and infections also increase susceptibility to pSS and PBC. Lifestyle and environmental factors, including cigarette smoking, nail polish, and hair dyes, significantly elevate the risk of developing these conditions (34, 35). Viral infections, particularly hepatitis C virus (HCV) and Epstein-Barr virus (EBV), are widely recognized as potential triggers of disease onset. HCV infection not only elevates the incidence of immune cryoglobulinemia in pSS patients but also plays a major role in hepatic involvement and serves as an important pathogenic contributor in PBC (35, 36). In addition, EBV antibodies or viral genetic material, along with autoantigens homologous to EBV antigens, have been detected in salivary gland epithelial cells (SGECs) and liver tissues, as well as in PBMCs of pSS and PBC patients (37, 38). Through molecular mimicry, EBV can induce abnormal autoantigen presentation and initiate autoimmune responses, thereby establishing a strong association with the pathogenesis of both diseases. Furthermore, EBV infection enhances autoantibody production in pSS and increases the risk of lymphoma among affected individuals (39).

3 Serological characteristics similarities

pSS and PBC are characterized by distinct serological biomarkers. pSS is typically diagnosed by the presence of serum anti-SSA and/or anti-SSB antibodies, together with an antinuclear antibody (ANA) titer of ≥1:320 (40). PBC is defined by the presence of serum anti-mitochondrial antibodies (AMA) at titers >1:40, typically accompanied by biochemical evidence of hepatic dysfunction, including elevated alkaline phosphatase (ALP) and γ-glutamyl transferase (GGT) levels (3, 41).

The ANA profile represents a spectrum of autoantibodies directed against various intracellular components, including nuclear, cytoplasmic, and cytoskeletal antigens. This profile encompasses ANA, AMA, anti-SSA, and anti-SSB antibodies, which serve as important biomarkers for the diagnosis of various autoimmune diseases and for the monitoring of disease activity.

In pSS, autoantibodies targeting SGECs, particularly anti-SSA (Ro52 and Ro60) and anti-SSB antibodies, are considered key mediators of autoimmunity. Anti-SSB antibodies generally coexist with anti-SSA antibodies, whereas the elevated titers of anti-SSA antibodies are closely associated with immune activation and reflect both the degree of inflammation and disease activity in pSS (42). Both in peripheral blood and MSGs, the detection rate of anti-SSA antibodies is significantly higher in pSS patients compared with non-pSS individuals, underscoring their diagnostic specificity (43). Anti-Ro52 antibodies are strongly correlated with increased serum levels of IgA and IgG (44). Patients with isolated anti-Ro52 positivity often present with higher rheumatoid factor (RF), while those positive for both anti-Ro52 and anti-Ro60 demonstrate more pronounced glandular inflammation, excessive B-cell activation, and elevated related biomarkers (45). Furthermore, the expression of interferon-stimulated genes is positively correlated with the presence of anti-Ro60 antibody (46).

AMA, as a specific biomarker for PBC patients, is capable of recognizing PDC-E2 antigen on the surface of biliary epithelial cells (BECs). Since PDC-E2 is also present on SGECs, AMA can similarly bind to these cells as well and mediate immune-mediated damage to SGECs. In addition to AMA, the 210 kDa glycoprotein (gp210), a nuclear pore membrane component, and the 100 kDa glycoprotein (sp100), associated with nuclear dots, are recognized as PBC-specific nuclear antibodies. AMA is detectable in the vast majority of PBC patients, and AMA-positive individuals typically exhibit elevated serum IgM levels. Anti-gp210 and anti-sp100 antibodies are detected in approximately 34% and 26% of patients, respectively. Although these markers demonstrate high diagnostic specificity, their sensitivity is relatively limited. Notably, gp210 antibody positivity correlates with significantly higher serum levels of ALT, GGT, ALP, and AST, as well as with poorer clinical prognosis. Thus, detection of anti-gp210 and anti-sp100 antibodies is of considerable clinical significance in PBC (47). Incorporating these tests into clinical practice can improve diagnostic accuracy in AMA-negative PBC, reduce the reliance on invasive liver biopsy, and enhance the overall reliability of non-invasive diagnostic approaches (48). Nevertheless, additional candidate biomarkers for the diagnosis of AMA-negative PBC remain under active investigation.

Anti-centromere antibodies (ACA) are detected in both pSS and PBC and may serve as an important serological marker for overlap syndromes, such as pSS combined with PBC onset (49, 50). In a cohort study involving 241 individuals with SS, systemic sclerosis, or PBC, as well as healthy controls, ACA was detected in 15% of SS patients and 20% of PBC patients (51). Among patients with pSS, ACA positivity is associated with markedly increased salivary gland fibrosis and more severe secretory gland dysfunction (52, 53), and distinct serological profiles with higher disease activity compared to ACA-negative individuals (54). In PBC, anti-gp210 antibody positivity correlates with the severity of interface hepatitis and lobular inflammation, while ACA-positive patients tend to follow a portal hypertension–dominant disease course accompanied by pronounced ductular reactions (55). Fibrotic changes predominate in ACA antibody-positive pSS, and ACA-positive PBC can predict a poor prognosis in the diagnosis of PBC (53, 56). Thus, the detection of ACA in combination with histological findings provides valuable diagnostic and prognostic information in both pSS and PBC.

4 Histologic similarities

Both pSS and PBC are characterized by varying degrees of progressive target-organ damage during disease progression and exhibit notable similarities in their histopathological features.

In pSS, histopathological changes in the minor salivary glands (MSGs) are characterized by lymphocytic infiltration surrounding the salivary ducts, leading to acinar atrophy and progressive destruction of glandular tissue. The infiltrating cells are predominantly CD4⁺ T lymphocytes, accompanied by B lymphocytes and plasma cells. Focal lymphocytic sialadenitis (FLS) is a defining pathological hallmark of pSS, and the presence of ≥50 lymphocytes within a 4 mm² area of salivary gland tissue constitutes one focus (FS = 1). A focus score (FS) ≥1 per 4 mm², in combination with serological findings, is considered diagnostic for pSS (40). As the disease progresses, extensive lymphocyte accumulation around ducts and invasion into follicles or epithelial cells result in follicular atrophy and disappearance, and ductal epithelial hyperplasia or luminal dilation. In advanced stages, ductal stenosis, obstruction, and fibrosis may occur, ultimately resulting in complete loss of exocrine function (57, 58). Notably, 10–30% of pSS patients develop ectopic germinal centers (eGCs) in their MSGs, which substantially increases the risk of lymphoma (59).

Patients with PBC progress through distinct pathological stages, including peribiliary inflammation, hepatic fibrosis, and ultimately cirrhosis. In the early phase, the liver demonstrates inflammatory changes resembling those seen in pSS, characterized by dense lymphocytic and plasma cell infiltration surrounding the bile ducts (60). This inflammatory infiltrate induces edema and degeneration of biliary epithelial cells, resulting in severe epithelial injury, disruption of the ductal basement membrane, lymphoid aggregates, and ductopenia, accompanied by mild to moderate hepatocellular necrosis, cellular swelling, and cholestasis. As the disease advances, inflammatory granulomas develop and contribute to the gradual loss of small intrahepatic bile ducts (2, 61). In stages III and IV, confluent fibrosis extends throughout the portal tracts and adjacent tissues, accompanied by progressive periportal cholestasis. Obstruction of the canalicular bile ducts ultimately results in cirrhosis and the formation of regenerative nodules. Moreover, owing to persistent lymphocytic aggregation, tertiary lymphoid structures (TLS), resembling ectopic germinal centers, emerge within the hepatic tissue of PBC patients (61, 62).

5 Tissue immune microenvironment similarities

The similarity in target tissue damage observed in pSS and PBC is primarily attributable to shared dysregulation of the immune microenvironment. This dysregulation is characterized by impaired function of epithelial cells and fibroblasts, aberrant activation of T and B lymphocytes, and dysregulated expression of various inflammatory mediators and cytokines (Figure 1).

Figure 1

Figure 1. The exocrine gland tissue in pSS and the bile duct tissue in PBC exhibit similar immune microenvironments. In this context, epithelial cells display aberrant expression of genes associated with hypoxia, senescence, and autophagy. Both SGECs and BECs abnormally present self-antigens, thereby becoming targets of autoimmune attack and creating a parallel immunopathological landscape. Fibroblasts release pro-inflammatory mediators and chemokines that recruit inflammatory cells; in PBC, aberrant expression of FAP and FGF further accelerates tissue fibrosis. NK cells show enhanced cytotoxicity, secreting perforin and granzyme, and infiltrate both MSGs and hepatic tissues, where they drive epithelial injury. Widespread macrophage infiltration upregulates genes linked to inflammation, tissue injury, and metabolic dysfunction, amplifying lymphocyte-mediated immune responses through co-stimulatory mechanisms. T and B lymphocytes both contribute to the initiation and persistence of inflammatory infiltrates in MSGs and bile ducts. T cells differentiate into distinct subsets and secrete cytokines, including IFNs, ILs, and TNFs, that perpetuate tissue inflammation and injury. The regulatory capacity of Tregs to maintain immune balance and homeostasis is impaired, while an imbalance in the Tfh/Tfr ratio leads to aberrant B cell activation. Enhanced cytotoxic activity of CD8⁺ T cells not only induces epithelial damage but also promotes B-cell antibody production. Following differentiation into Trm cells, B cells persist within tissues, sustaining local immune activation. Ultimately, B cells and plasma cells in eGCs generate diverse autoantibodies that exacerbate both local and systemic tissue damage. pSS, primary Sjogren’s syndrome; PBC, primary biliary cholangitis; SGECs, salivary gland epithelial cells; BECs, biliary epithelial cells; FAP, fibroblast activation protein; FGF, fibroblast growth factor; NK cells, natural killer cells; MSGs, minor salivary glands; IFN, interferon; ILs, interleukins; TNF, tumor necrosis factor; BAFF, B cell activating factor; Th, T helper; Tregs, regulatory T cells; Tfh, T follicular helper; Tfr, follicular regulatory T cells; Trm, tissue-resident memory T cells; HIF-1α, hypoxia-inducible factor 1α; 2-OAD, 2-oxoglutarate dehydrogenase; 8-OHdG, 8-hydroxy-2’-deoxyguanosine; HEL, hexanoyl lysine; ROS, reactive oxygen species; CCL, chemokine (C-C motif) ligand; CXCL, chemokine C-X-C motif ligand; CD, cluster of differentiation; AMA, antimitochondrial antibodies; anti-SSA/SSB, anti-Sjogren’s syndrome A/B; eGCs, ectopic germinal centers.

5.1 Non-immune tissue cells

5.1.1 Epithelial cell

SGECs and BECs play a pivotal role in shaping the immune-dysregulated microenvironment. In pSS and PBC tissues, epithelial cells facilitate autoantibody recognition through their antigen-presenting function. They also produce pro-inflammatory cytokines, adhesion molecules, and chemokines, which promote B-cell activation and T-cell infiltration. These signals recruit and retain immune cells in the tissue, ultimately sustaining chronic inflammation.

Within epithelial cells, increased production of reactive oxygen species (ROS) and exacerbated mitochondrial damage disrupt microcirculation and mitochondrial metabolism, leading to heightened local tissue hypoxia and promoting cellular apoptosis. In the MSGs of pSS patients, oxidative stress markers such as 8-hydroxy-2’-deoxyguanosine (8-OHdG) and hexanoyl-lysine (HEL) are elevated, reflecting a pro-oxidant state in the tissue (63). In the liver tissue of PBC patients, 2-oxoacid dehydrogenase (2-OAD) activity is impaired, hypoxia-inducible factor 1α (HIF-1α) secretion is increased, and PDC-E2 fails to properly participate in intracellular redox reactions. These alterations exacerbate mitochondrial dysfunction and aggravate hepatic hypoxia (64). The resulting hypoxic microenvironment promotes the release of inflammatory factors from immune cells, causing abnormal macrophage activation, Th17 differentiation, and an imbalance in Treg cell populations. Collectively, these changes enhance lymphocyte infiltration and tissue injury, thereby accelerating hepatic fibrosis and worsening cholestasis in PBC patients.

Dysregulation of cellular senescence and autophagy mechanisms is closely implicated in the pathogenesis of autoimmune diseases. Cellular senescence is a manifestation of cessation of cell proliferation processes and substantial alterations in gene expression, while autophagy is a protective catabolic process that degrades misfolded proteins and damaged organelles. Both processes serve to delay apoptosis by mitigating cellular damage, stabilizing cellular homeostasis, and maintaining metabolic homeostasis. In pSS patients, however, the expression of senescence markers p16 and p21 is significantly elevated in MSGs, and epithelial cells exhibit impaired self-renewal capacity. Even after the resolution of inflammatory infiltration in the MSGs, salivary gland function fails to recover (65). Autophagy-related genes are upregulated in the MSGs of pSS patients, and the increased expression of LC3, an autophagosome marker in lymphocytes, promotes the secretion of IL-23 and IL-21, thereby exacerbating inflammation and tissue damage (66). Animal experiments have shown that correcting autophagy dysregulation in aged mice reduces the formation of TLS in SG and ameliorates glandular pathology (67). In PBC patients, BECs in damaged small bile ducts display significantly shortened telomeres and markedly elevated expression of the senescence-associated secretory phenotype (68). LC3 is also strongly expressed in BECs and co-localizes with senescence markers p16 and p21 in inflamed bile ducts (69). Moreover, p16 expression is closely correlated with the staging of PBC (70).

In pSS and PBC patients, interconnected mechanisms, including cellular senescence, dysregulated autophagy, and oxidative stress, are interconnected, leading to widespread epithelial cell damage and enhanced immune responses. These factors collectively accelerate disease progression and identify potential targets for therapeutic intervention.

5.1.2 Fibroblast

Fibroblasts are widely distributed across tissues and secrete cytokines, including B lymphocyte stimulator (BLyS) and IL-7, chemokines like CXCL13, CCL19, and CCL21, and growth factors. These factors collectively facilitate lymphocyte transendothelial migration, promote cell development, proliferation, and differentiation, and help maintain tissue structural integrity. In the context of autoimmune diseases, inflammation-associated fibroblasts exhibit dysregulated cytokine production and altered functional responses through the activation of downstream signaling pathways.

In pSS patients, fibroblasts in the MSGs form an intricate network of interactions with surrounding cells. These fibroblasts exhibit significant downregulation of signaling pathways related to SGECs’ growth and extracellular matrix components, such as collagen and laminin, while pro-inflammatory pathways are markedly upregulated. This dysregulation impairs epithelial regeneration and glandular development, triggering a cascade of inflammatory responses in pSS (71). In pSS, fibroblasts aberrantly express chemokines such as CCL21 and CCL19, recruiting lymphocytes and contributing to the formation of TLS under the influence of IL-22 and lymphotoxins, thereby exacerbating inflammatory infiltration within pSS tissues (72, 73). Additionally, fibroblasts express CD21, a complement receptor 2, or the EBV virus receptor. EBV can exploit this receptor to abnormally activate B cells, which may play a role in triggering pSS in otherwise healthy individuals following EBV infection (74).

In PBC patients, fibroblast-like cells and stromal deposits accumulate in the periductal regions of proliferating bile ducts, representing a key contributor to hepatic fibrogenesis. The inflammatory environment within the liver upregulates the expression of fibroblast activation protein on fibroblasts (75). In concert with pro-fibrotic activation of hepatic stellate cells and extracellular matrix deposition, this process exacerbates both fibrotic histopathology and inflammatory infiltration, establishing a positive feedback loop that perpetuates tissue scarring and inflammation. In addition, fibroblast growth factor 19 interacts with the bile acid receptor FXR to downregulate hepatic bile acid levels. However, in PBC, the abnormal expression of fibroblast growth factor 19 and dysregulated FXR interactions disrupt bile acid homeostasis, intensifying cholestasis and promoting liver injury (76).

5.2 Immunocyte

5.2.1 Natural killer cells

Natural killer (NK) cells are innate immune lymphocytes capable of exerting cytotoxic effects and releasing cytokines without prior antigen exposure. Their cytotoxic activity promotes apoptosis of SGECs and BECs through the secretion of perforin and granzyme, as well as through activation of the Fas/FasL signaling pathway.

Both pSS and PBC demonstrate significant genetic enrichment related to NK cells (4). In the MSGs of pSS patients and the liver of PBC patients, NK cells accumulate around infiltrating lesions, exhibit heightened cytotoxicity, and show markedly increased perforin expression (77, 78). Guided by the CX3CL1/CX3CR1 axis, NK cells migrate to and persist within MSGs and hepatic tissues; they further promote local immune infiltration through CCL3 and CCL5, thereby reinforcing the abnormal immune microenvironment, amplifying local immune responses, and accelerating disease progression in both pSS and PBC (79).

5.2.2 Monocyte-macrophage cell

Macrophages regulate the immune responses by secreting inflammatory cytokines and chemokines that coordinate interactions among various components of the immune system. Through Toll-like receptor (TLR) signaling, they provide co-stimulatory signals that recruit lymphocytes and amplify immune activation. Critically, macrophages are indispensable for the activation of CD4⁺ T cells and for supporting the development and maturation of B cells.

In pSS patients, the proportion of macrophages is elevated in damaged glandular tissues, where they persist around autoimmune lesions (80). Infiltrating M1 macrophages amplify the expression of genes associated with inflammation, tissue injury, and metabolic dysregulation, while releasing pro-inflammatory cytokines such as IL-6, TNF-α, and IL-12. Although M2 macrophages secrete anti-inflammatory mediators, accumulating evidence indicates that they may emerge during later disease stages and contribute to glandular fibrosis in the context of chronic inflammation (81). Kupffer cells, the resident macrophages of the liver, also play a pivotal role in PBC. In these patients, macrophages exhibit upregulated expression of Engulfment and Cell Motility 1 (ELMO1), which activates the NF-κB signaling pathway, promotes macrophage migration into the hepatic tissue, and enhances both cytokine secretion and phagocytic activity (82). Through these mechanisms, macrophages intensify local inflammatory responses and aggravate cholestasis.

5.2.3 T-lymphocyte cells

T and B lymphocytes act in concert to drive inflammatory infiltration within glandular and tissue sites. Aberrant activation of CD4⁺ T cells promotes tissue inflammation through the secretion of pro-inflammatory cytokines such as IFN-γ, IL-17, and TNF-α, and facilitates the differentiation of CD8⁺ T cells into cytotoxic effectors that mediate tissue damage. In addition, T cells are critically involved in promoting B cell development, proliferation, and activation, as well as in the formation of TLS, thereby enhancing autoantibody production and further aggravating tissue injury.

5.2.3.1 Th1 and Th2 cells

Th1 cells primarily induce epithelial cell apoptosis through the secretion of pro-inflammatory cytokines such as IFN-γ and TNF-α. They also facilitate antigen clearance through enhancing antigen presentation and promoting the activation of immune cells. Th2 cells promote B cell activation and antibody production via the secretion of cytokines, including IL-4 and IL-5, thereby playing a pivotal role in antibody-mediated immune responses. However, when the activity of both Th1 and Th2 subsets is abnormally elevated, the immune system may aberrantly present self-antigens and initiate destructive responses against host tissues, ultimately contributing to the development of autoimmune diseases.

In patients with pSS and PBC, cytokines secreted by Th1 and Th2 cells selectively recruit helper and cytotoxic T cell subsets, promote aberrant Th17 differentiation, and induce abnormal activation of B cells and NK cells. These events disrupt lymphocyte distribution and tissue homeostasis, ultimately leading to increased IgM and IgA production. In the MSGs of pSS patients, infiltration of Th1 and Th2 cells is elevated, accompanied by significantly increased transcription of cytokine and chemokine genes associated with these subsets (83). Similarly, in PBC, Th1- and Th2-related transcripts are upregulated and expressed disproportionately in both blood and liver (84). In the early stage of PBC, IFN-γ- and CXCR3-expressing Th1 cells accumulate around damaged bile ducts, releasing inflammatory mediators that sustain hepatic inflammation by recruiting lymphocytes and other immune cells. As the disease progresses, portal lymphocytes differentiate into Th1 cells, becoming key mediators of persistent bile duct injury (85). Thus, the heightened expression and imbalance of Th1/Th2 subsets perpetuate chronic inflammation and exacerbate tissue damage, playing a central role in the pathogenesis and progression of both pSS and PBC.

5.2.3.2 Th17 and Treg cells

Th17 cells mediate pro-inflammatory responses by secreting cytokines such as IL-17, IL-22, and IL-23, while they also recruit lymphocytes to initiate and amplify local inflammation. In patients with pSS, IL-17 levels are significantly elevated in peripheral blood, and IL-17-producing cells are abundantly infiltrated within MSG lesions (86). Experimental knockdown of ubiquitin-specific peptidase 18 in murine models reduces the proportion of Th17 subsets within salivary glands, restores Treg subsets in salivary glands, improves salivary flow rates, and attenuates lymphocytic infiltration (87). In advanced PBC, IL-17⁺ cells are markedly increased in the liver and accumulate around BECs (88). The IL-23/IL-17 axis promotes lymphocyte differentiation into Th17 cells and enhances IFN-γ production, thereby skewing immune responses toward a Th17-dominant phenotype and sustaining hepatic inflammation. BECs express IL-17 receptors that respond directly to IL-17, further promoting autoinflammation. Moreover, IL-17 derived from PBC patients strongly stimulates the proliferation of hepatic stellate cells, thereby accelerating hepatic fibrosis (89).

Tregs, which are central to maintaining immunoregulatory balance and immune homeostasis, suppress excessive immune responses by modulating the inflammatory milieu or by directly inducing apoptosis in T cells. Treg deficiency has been closely implicated in the early onset of pSS. In murine models, SATB1 gene knockout results in Treg depletion, which exacerbates lymphocytic infiltration in the SGs and induces SS-like manifestations (90). In PBC, the hepatic microenvironment is enriched with pro-inflammatory cytokines such as IL-6, IFN-γ, and IL-1β, but is deficient in IL-2. This cytokine imbalance destabilizes Tregs and compromises their suppressive capacity against lymphocyte proliferation (91). Clinically, PBC patients exhibit markedly reduced circulating Treg frequencies, which correlate with elevated serum ALT levels and increased autoantibody expression (48). Importantly, patients with overlapping pSS and PBC present a more profound Th17/Treg imbalance and more severe hepatic dysfunction (92). Taken together, Treg deficiency or functional impairment represents a critical factor driving immune dysregulation and disease progression in both pSS and PBC.

Recent studies have identified FoxP3 demethylation as a key mechanism impairing Treg function (93). In pSS patients, the number of FoxP3⁺ Tregs in MSGs correlates positively with the degree of inflammatory infiltration (94). FoxP3 demethylation exacerbates PBC progression by compromising Treg function (95). Moreover, complete ablation of FoxP3⁺ Tregs in animal models induces a PBC-like phenotype characterized by anti-AMA antibody production (96). Loss of Treg-mediated suppression promotes the expansion of pathogenic Th17 cells and excessive production of Th17 cytokines, while Treg depletion amplifies pro-inflammatory signaling across diverse immune cell populations. Conversely, restoring functional Tregs within glandular and hepatic tissues can reestablish a balanced lymphocyte microenvironment, attenuate excessive inflammation, and alleviate disease severity, thereby representing a promising therapeutic approach for both pSS and PBC.

5.2.3.3 Tfh and Tfr cells

T follicular helper (Tfh) cells secrete cytokines that enhance the activation and proliferation of B cells, which in turn regulate the development of B cells towards mature plasma cells and memory cells and promote TLS formation and B cell antibody production. Conversely, follicular regulatory T (Tfr) cells, a specialized subset of Tregs, suppress immune responses by secreting immunosuppressive cytokines or competing with Tfh cells for ligand engagement, thereby limiting B cell differentiation and functional activity.

In both pSS and PBC, Tfh cells exhibit aberrant upregulation of inducible T cell costimulator (ICOS), programmed death receptor 1 (PD-1), enhancer of zeste homolog 2 (EZH2), and chemokines (97, 98). This dysregulation, mediated by enhanced STAT phosphorylation under the regulation of IL-21 and Bcl6, drives quantitative and functional abnormalities in Tfh cells while concurrently suppressing Tfr cell proliferation and activity. As a result, B cells become excessively activated within tissues, producing increased autoantibodies and amplifying autoimmune responses. In pSS, Tfh and B cells accumulate in the MSGs at later stages and display a synchronized developmental trajectory. The frequency of activated Tfh cells correlates positively with anti-SSB antibody levels and serum IgG concentrations (99), highlighting the pathogenic significance of Tfh-B cell interactions in disease progression. In PBC, an imbalanced Tfr/Tfh ratio promotes aberrant B cell activation, excessive IgM secretion, enhanced lymphocyte chemotaxis, and increased death of normal cells. Impaired Tfr function also diminishes inhibition of TLS formation, further elevating local antibody production. Restoring the Tfr/Tfh balance improves GC-related factor expression, reduces tissue lymphocyte infiltration, and may mitigate autoimmune pathology. Currently, the Tfr/Tfh ratio has been proposed as a potential biomarker to differentiate clinical manifestations of pSS and PBC; however, its specificity and sensitivity require further validation.

5.2.3.4 CD8⁺ effector T cells

CD8⁺ effector T cells, also known as CD8⁺ cytotoxic T lymphocytes, can specifically recognize self-antigens presented by MHC class I molecules. By releasing cytokines such as IFN-γ and TNF, together with cytotoxic effector molecules including granzyme and perforin, they directly induce lysis of target cells. In pSS and PBC patients, tissue-infiltrating CD8⁺ T cells mediate direct cytotoxic effects on epithelial cells, thereby amplifying local inflammatory responses and aggravating epithelial injury.

In pSS patients, CD8⁺ T lymphocytes in the MSGs exhibit markedly elevated expression of granzyme K and heat shock proteins, enhancing their cytotoxicity against self-antigens and contributing to persistent stress responses and low-grade glandular inflammation (100). In early-stage PBC, CD8⁺ T cells recognize MHC class I-restricted PDC-E2 epitopes on BECs, mediating aberrant antigen presentation and inducing BEC apoptosis. Under the influence of excessive IFN-γ secretion by CD4⁺ T cells, these CD8⁺ T cells further amplify bile duct inflammation, ultimately leading to epithelial injury (101). In advanced disease, an imbalance between CD8⁺ T cells and Tregs, together with a pronounced infiltration of CXCR6⁺CD8⁺ T cells in the peribiliary region, drives aggravated hepatic inflammation, intensifies extensive bile duct injury, and accelerates hepatic fibrosis in PBC patients (102).

CD8⁺ tissue-resident memory T cells (Trm) represent a distinct memory T cell subset that resides independently of the peripheral circulation. Residing long-term in peripheral non-lymphoid tissues, they provide rapid and localized defense against reinfection by specifically recognizing PDC-E2, directly eliminating target cells, or secreting antiviral cytokines. In the SGs of SS murine models, Trm cells exhibit hyperproliferation and hyperactivation, producing high levels of inflammatory mediators, recruiting CXCR3⁺ T cells, and accelerating epithelial cell injury through the Fas/FasL pathway and cytotoxic mechanisms (103). CD8⁺ Trm cells localize within the MSG epithelium via integrin CD103-mediated adhesion, while CD69 expression enables them to resist the chemotactic gradient of sphingosine-1-phosphate in blood and lymphatic vessels, thereby preventing their recirculation (104). In the specialized hepatic immune microenvironment of PBC patients, CD8⁺ T cells upregulate E-cadherin, which interacts with the E-cadherin/β-catenin complex to form adhesive junctions. This facilitates their accumulation around BECs and promotes retention within bile ducts, thereby modulating lymphocyte infiltration and contributing to hepatic inflammation and fibrosis (105).

5.2.4 B-lymphocyte cells

5.2.4.1 Breg

Regulatory B cells (Bregs) constitute an immunosuppressive B cell subset that plays a critical role in maintaining immune tolerance and preventing autoimmunity. They primarily mediate their immunoregulatory effects through the secretion of anti-inflammatory cytokines, including IL-10 and IL-35, in response to immune activation (106). The key functions of Bregs encompass the inhibition of pro-inflammatory Th1 and Th17 cell differentiation, suppression of Tfh cell responses, and the potential induction of Treg expansion (107).

In autoimmune conditions such as pSS, the frequency of Breg cells shows a progressive decline. And this loss of immunosuppressive function parallels Tfh cell expansion, disruption of the inflammatory milieu, and increased disease activity (106). Some studies have reported an increased proportion of CD19⁺CD24^hiCD38^hi Breg cells in pSS patients during both active and inactive phases of the disease (108), which may represent a compensatory immunoregulatory mechanism. However, whether these cells retain full functional capacity remains uncertain. In PBC, peripheral Breg cell numbers are increased, but their function is impaired, resulting in excessive activation of Th1 and Th17 cells and suppression of Treg activity. These functional abnormalities further exacerbate disease severity and correlate with elevated biochemical indicators, such as ALP (109).

5.2.4.2 Memory B cells

Memory B cells, as the principal carriers of adaptive immune memory, exhibit pronounced abnormalities in both distribution and function in patients with autoimmune diseases. Upon antigenic stimulation, naïve B cells differentiate into plasma cells or memory B cells. In pSS and PBC, chemokines secreted by epithelial cells within inflamed tissues recruit circulating memory B cells to the affected glands and promote their local retention. In addition to enhancing CXCL13-mediated B cell chemotaxis, memory B cells also participate in the formation of eGCs with the support of Tfh cells, thereby further amplifying B cell activation and sustaining local autoimmune responses.

In patients with pSS, the proportion of CD27⁺ memory B cells in peripheral blood is markedly reduced; in contrast, a pronounced accumulation of memory B cells is observed within affected MSG tissues, suggesting a potential redistribution (110). This chemotactic behavior is likely mediated by the elevated expression of chemokine receptors CXCR4 and CXCR5, which respond to gradients of CXCL12 and CXCL13 secreted by epithelial cells in the inflamed glands (111). Within the exocrine glands of SS patients, memory B cells further promote the formation of GC structures, thereby amplifying B cell chemotaxis and driving lymphocytic infiltration (112). Similarly, in PBC patients, the frequency of circulating CD27⁺CD19⁺ memory B cells is significantly reduced compared with healthy controls, likely reflecting antigen-specific memory B cell redistribution from lymphoid tissues to sites of inflammation and away from the peripheral circulation (113).

5.2.4.3 Plasma cells

Plasma cells (PCs) are terminally differentiated B cells that serve as the principal source of antibodies and immunoglobulins. Their abundance and functional activity are closely associated with the serological profiles and pathological damage observed in autoimmune diseases.

The survival and functionality of PCs are highly dependent on microenvironmental signals, particularly BAFF and IL-6. BAFF, induced by type I interferons, provides essential survival signals to PCs (114). PCs also exhibit chemotaxis toward sites rich in CXCL12 and IL-6, relying on these factors to sustain long-term survival and continuous antibody secretion (115). In the context of autoimmune pathology, T cells secrete IL-21 and ICOS to drive B cell differentiation into PCs, while BAFF overexpression further maintains their persistence. With assistance from Tfh cells, PCs potentiate autoimmune responses through the production of copious autoantibodies and immunoglobulins (116, 117).

Aberrant activation of PCs represents a key factor underlying the elevated titers of autoantibodies observed in patients with pSS and PBC. In patients with pSS, PCs are recruited into the MSGs via CXCL12-mediated chemotaxis and distribute across different glandular regions. The IL-6-enriched microenvironment provides a survival niche that sustains prolonged secretion of antibodies, including IgA and IgG, and contributes to increased serum ANA titers (115). In PBC, the frequency of PCs producing PDC-E2-specific antibodies is markedly improved. With additional support from Tfh cells and other cytokines, this dysregulated activation exacerbates disease activity and drives abnormalities in biochemical markers (118).

Immunophenotypic analyses have demonstrated the coexistence of IgA- and IgG-expressing PCs in the MSG tissues of patients with pSS. IgA⁺ PCs tend to form small clusters adjacent to ductal and epithelium, whereas IgG⁺ PCs are distributed throughout both the central and peripheral regions of larger focal infiltrates (115). The extent of lymphocytic infiltration influences both the clustering of PCs and the levels of IgG expression. In PBC, elevated serum IgM and IgG levels can be attributed to enhanced T–B cell interactions mediated by lymphokines. In this process, activated T cells secrete B cell growth factor and B cell differentiation factor, which promote B cell proliferation and ultimately drive their differentiation into PCs capable of secreting immunoglobulins, thereby contributing to increased immunoglobulin production (115).

Notably, the coexistence of PBC and pSS is closely linked to elevated IgM levels. A retrospective analysis of 82 patients with concomitant pSS and PBC demonstrated that the frequency of increased IgM in PBC patients with SS (53.7%) was markedly higher than in the pSS-only group (6.1%) (119). In addition, anti-SSA-positive PBC patients showed higher serum bilirubin and IgM levels, accompanied by more severe histological progression (120). Thus, elevated IgM represents a significant risk factor for the development of PBC in the context of pSS. Collectively, these observations underscore the pivotal role of abnormal PC activation and autoantibody production in the immunopathogenesis of both diseases.

5.2.4.4 Ectopic germinal centers

Within the tissue immune microenvironment, inflammatory mediators drive aberrant activation of B lymphocytes and their migration into non-lymphoid tissues. In these sites, B cells interact with T cells, GC B cells, and the follicular dendritic cell network to promote the formation of eGCs. These structures, also referred to as tertiary lymphoid organs or ectopic lymphoid structures, play a pivotal role in sustaining chronic inflammation and autoimmunity.

Aberrant activation and differentiation of GC B cells constitute a central mechanism driving disease progression, regulated by a complex network of cytokine signaling and intercellular interactions. Elevated expression of CXCR4, CXCL12, and CXCL13 facilitates extensive lymphocyte infiltration into eGCs, aggravating glandular destruction and functional impairment. At the same time, the accumulation of autoantibodies facilitates immune complex formation, which can trigger diverse extra-glandular manifestations (121, 122). Plasmacytoid dendritic cells secrete IFN-I, thereby inducing the production of BAFF. BAFF not only enhances B-cell survival but also serves as a bridge between innate and adaptive immunity, sustaining chronic B-cell hyperactivation (123). Elevated BAFF levels may further sustain the activation and local accumulation of autoreactive B cells, ultimately fostering the maturation and maintenance of eGCs (124).

eGCs exhibit a secondary lymphoid organ-like structure, comprising follicular dendritic cell networks and high endothelial venules. This specialized microenvironment is conducive to high-frequency somatic hypermutation, antibody class switching, and efficient autoantibody production, and also markedly increases the risk of lymphomagenesis (124, 125).

The progression of pSS is characterized by increased periductal cellular infiltration and the establishment of eGCs within salivary glands, accompanied by autoantibody production. In MSGs, these eGCs exhibit GC-like architecture that drives markedly elevated levels of anti-SSA/SSB antibodies and RF. They are also associated with increased concentrations of local and systemic pro-inflammatory mediators, including CCL11, IFN-γ, and BAFF, thereby substantially elevating the risk of lymphomagenesis (126, 127). Similarly, in PBC, eGCs represent a hallmark feature characterized by lymphocyte accumulation in portal tracts, with their maturation correlating closely with disease-associated inflammation and fibrosis. Dysregulation of the Tfr/Tfh ratio in PBC patients impairs the inhibitory function of Tfr cells on GC formation. This loss of regulation, together with a cellular phenotype defined by high expression of CXCR5, PD-1, ICOS, and Bcl6, further exacerbates lymphocyte infiltration and epithelial cell death, exacerbating disease pathology (98).

5.3 The similarities in cytokines and chemical signaling molecules

5.3.1 Interleukin

ILs are cytokines secreted by diverse immune cells that regulate immune responses and inflammation. They also facilitate antigen presentation and promote the proliferation and differentiation of immune cells.

In the MSGs of patients with pSS, multiple ILs act in concert to shape the immune microenvironment. Dysregulated expression of IL-4 and IL-40 establishes a positive feedback loop that exacerbates tissue injury. IL-4 activates the JAK1/STAT6 pathway to promote Th2 cell differentiation and enhance immunoglobulin G (IgG) secretion by B cells. Driven by aberrant IL-4 production, IL-40 accelerates B lymphocyte activation and demonstrates a positive correlation with ESSDAI scores in pSS patients (128). Excessive secretion of IL-27 promotes activation of the NLRP3 inflammasome, contributing to immune infiltration of the salivary and lacrimal glands through STAT1- and STAT3-dependent signaling, ultimately leading to glandular damage (129). IL-7 and its receptor (IL-7R) are strongly associated with the formation of ectopic lymphoid structures in the MSGs of pSS patients (130). IL-33 further amplifies immune dysregulation by acting synergistically with IL-12 and IL-23 on NK cells to promote IFN-γ production, thereby intensifying local inflammation. Apoptotic SGECs also overexpress IL-33, which activates downstream inflammatory pathways. Elevated IL-33 expression has been proposed as a signal of autoimmune dysregulation and correlates clinically with ocular disease severity in pSS patients (131).

In PBC patients, deficiency of IL-2, an important growth factor that maintains the development of Treg cells, within hepatic tissues suppresses Treg function, thereby aggravating lymphocyte imbalance and promoting aberrant immune responses (132). IL-12 plays a pivotal role in the onset of early biliary inflammation by enhancing IFN-γ production in Th1 cells through the STAT4 signaling pathway, ultimately contributing to hepatic pathology (133). Within the unique immune microenvironment of the PBC liver, the function of interleukins is profoundly altered. Aberrant secretion of IL-37 further amplifies IFN-γ production and promotes the induction of the NK cell–attracting chemokine CCL5. This process, in turn, increases the intrahepatic accumulation of NK and NKT cells, driving persistent inflammatory infiltration and tissue injury (134).

Serum interleukin levels in patients with pSS and PBC represent critical determinants of tissue immune infiltration. In pSS, elevated serum concentrations of IL-6 and IL-9 activate the JAK2/STAT3 signaling pathway, promoting the differentiation and survival of CD4⁺ T cells into Th17 subsets and enhancing IL-17 secretion. These processes establish an inflammatory microenvironment that exacerbates local immune dysregulation and tissue inflammation (135, 136). In PBC, reduced IL-35 expression in the peripheral circulation is associated with heightened T cell-mediated inflammation and cytotoxicity, contributing to progressive abnormalities in liver function tests. Conversely, increased IL-35 expression within tissues impairs Treg activity, indirectly amplifies Th17-mediated immune responses, and accelerates biliary epithelial damage and hepatic fibrogenesis (137).

In patients with pSS and PBC, multiple ILs contribute to abnormal lymphocyte differentiation and distribution within glands and tissues through shared mechanisms, thereby impairing secretory function. IL-21 promotes Th17 differentiation and, together with IL-23, drives lymphocyte expansion. In addition, IL-21 enhances BAFF receptor signaling in B cells or acts directly on B cells to facilitate antibody production. It also induces epithelial cell apoptosis through the Fas/FasL and perforin/granzyme B pathways. IL-23 further supports memory T-cell differentiation and sustains the survival and effector function of Th17 cells. Several interleukins converge on the upregulation of IL-17, primarily through expansion of the Th17 cell population. IL-17 activates both the canonical TGF-β1/Smad2/3 pathway and the non-canonical TGF-β1/Erk1/2 pathway, thereby intensifying tissue inflammation and fibrosis. Elevated IL-17 and IL-23 levels have been detected in the peripheral blood and tissues of patients with pSS and PBC, where they act in a positive feedback loop to amplify inflammation and tissue damage. Clinically, monitoring IL-17 and IL-23 levels may provide value for the early diagnosis of pSS and for staging disease progression in PBC (138–140).

5.3.2 Interferon

IFNs regulate immune responses through the JAK/STAT signaling pathway and other signaling cascades, playing pivotal roles in both innate and adaptive immunity. IFN-α disrupts immune tolerance and induces epithelial cell apoptosis by upregulating MHC class I and II expression and activating antigen-presenting cells. It also promotes lymphocyte proliferation and activation, thereby enhancing autoantibody production. IFN-β shares downstream signaling with IFN-α and exerts primarily anti-inflammatory and anti-proliferative effects (141). IFN-γ enhances innate immune responses by activating the JAK/STAT and NF-κB pathways, drives Tfh cell differentiation and CD8⁺ T cell activation, and contributes to the formation of eGCs and the induction of pathogenic autoantibodies (142).

In patients with pSS, overexpression of IFN-I exacerbates the generation of ROS, induces intracellular oxidative stress, and disrupts normal cellular metabolism. IFN-I further activates key inflammatory pathways, including NF-κB and the NLRP3 inflammasome, thereby amplifying tissue inflammation. Under hypoxic conditions, excessive IFN-I aggravates mitochondrial damage, exacerbates hypoxia, and promotes aberrant apoptotic processes (143). IFN-γ promotes epithelial cell pyroptosis and apoptosis by activating the JAK/STAT1 pathway and upregulating MHC class II expression. In addition, IFN-γ inhibits the cystine/glutamate antiporter system Xc^-, triggering ferroptosis in SGECs and ultimately impairing MSGs’ function (144).

The mRNA expression levels of IFNs and TLRs are significantly elevated in PBC patients and are distributed across distinct hepatic regions and cell types (145). Enhanced TLR signaling further stimulates IFN- I production, thereby sustaining chronic inflammation and exacerbating autoimmunity. In murine models of PBC, pharmacologic inhibition of the JAK1/2 pathway effectively reduced IFN-γ levels, alleviated portal inflammation and bile duct injury, and decreased CD4⁺ and CD8⁺ T cell infiltration in both the spleen and liver (142). Moreover, female cells exhibit markedly higher IFN-γ production than male cells, highlighting IFN as a key contributor to the sex bias observed in PBC pathogenesis (146).

In pSS patients, peripheral blood IFN-I expression correlates strongly with the production of anti-SSA and anti-SSB antibodies, and is particularly elevated in individuals harboring both anti-Ro52 and anti-Ro60 subtypes (147). In PBC, IFN promotes the generation of sp100 autoantibodies, increases serum AMA antibody levels in PBC murine models, and stimulates CD8⁺ T cell responses that mediate bile duct epithelial injury (148, 149). Thus, elevated IFN expression in both pSS and PBC not only drives abnormal epithelial apoptosis and tissue damage but also exacerbates autoimmunity by facilitating pathogenic autoantibody production.

5.3.3 Tumor necrosis factor

TNF-α, primarily produced by macrophages, plays a central role in orchestrating inflammatory and oxidative processes. It is also implicated in the pathogenesis of chronic hepatic inflammation and fibrosis and is closely linked to BECs injury. In pSS patients, elevated TNF-α levels enhance B-cell activation, thereby promoting the production of IgG, anti-SSA, and anti-SSB antibodies (150). In addition, TNF-α activates the NF-κB signaling pathway, inducing epithelial cell apoptosis and amplifying inflammatory responses. In PBC mouse models, elevated levels of TNF-α or IFN-γ disrupt the barrier function of the tight junction-associated protein 7H6 through NF-κB activation, leading to increased paracellular permeability of cholangiocytes and further disruption of bile duct integrity (151).

B cell activating factor (BAFF), also known as B lymphocyte stimulator (BLyS), is a critical regulator of B cell survival and maturation. By engaging the BAFF receptor (BAFF-R) on B cells it governs B cell differentiation and immune tolerance. In cooperation with a proliferation-inducing ligand (APRIL), BAFF promotes B cell survival, proliferation, and activation, thereby maintaining peripheral B cell homeostasis, sustaining the B cell pool, and supporting humoral immunity. BAFF constitutes a central pathogenic mediator in both pSS and PBC, with its levels closely correlated with autoantibody and immunoglobulin production. In pSS, serum BAFF and APRIL levels are significantly elevated, driving B cell activation, increasing serum IgG secretion, and promoting the generation of anti-SSA and anti-SSB antibodies, thereby intensifying autoimmune responses (152). In addition, BAFF expression is markedly upregulated within inflammatory cells infiltrating the MSGs of pSS patients, where it promotes focal lymphocyte aggregation and eGCs formation, ultimately elevating the risk of lymphoma development (153, 154). In PBC, elevated serum BAFF levels stimulate the production of IgM, IgG, and AMA. It also indirectly contributes to Tregs’ apoptosis and functional impairment, thereby altering the immune microenvironment of biliary epithelial cells (152, 155, 156). Excessive BAFF further aggravates hepatic injury by elevating aminotransferase and bilirubin levels, sustaining hepatocyte necroinflammation, exacerbating cholestasis, and promoting progressive liver fibrosis (157). Collectively, aberrant B cell activation serves as a key mechanistic link between pSS and PBC, with elevated BAFF levels playing a pivotal role in the shared pathogenesis of these two autoimmune diseases.

5.3.4 Chemokines

Aberrant chemokine expression plays a critical role in the pathogenesis of autoimmune responses. Chemokines produced by SGECs and BECs selectively orchestrate the recruitment and homing of distinct lymphocyte subsets, thereby facilitating inflammatory cell infiltration and activating immune cells such as T cells, macrophages, and NK cells. These processes contribute to tissue inflammation and mediate progressive injury to exocrine glands and bile ducts. In patients with pSS and PBC, chemokine levels are elevated to varying degrees across multiple tissues and organs. The specific functions and clinical implications of chemokines involved in immune cell recruitment in pSS and PBC are summarized in Table 2.

Table 2

Table 2. pSS and PBC-associated chemokines and their functions and clinical manifestations.

CX3CL1 is a chemokine with dual functions in lymphocyte recruitment and cell adhesion. Acting through its receptor CX3CR1, it mediates the recruitment of intraepithelial lymphocytes and facilitates the migration and accumulation of macrophages and NK cells. CX3CL1 is upregulated to varying degrees in patients with both pSS and PBC. In pSS, CX3CL1 and CX3CR1 are primarily localized in salivary and lacrimal glands, where they drive immune cell infiltration and are associated with eGCs formation. Experimental blockade of the CX3CL1/CX3CR1 axis in SS mouse models reduced M1 macrophage infiltration, alleviated SG inflammation, and restored glandular function (174). In PBC, CX3CL1 upregulation mainly occurs in senescent BECs, where it facilitates the migration and accumulation of CX3CR1⁺ lymphocytes around bile ducts. In turn, this process exacerbates lymphocytic bile duct inflammation via activation of the NF-κB signaling pathway (167).

CXCL12, a B-cell growth factor, promotes lymphangiogenesis and regulates the activation, adhesion, and homing of CXCR4⁺ cells. In patients with pSS, CXCL12⁺ cells are highly expressed in B-cell-infiltrated salivary and lacrimal glands, particularly within malignant B cells, and this upregulation is associated with an increased risk of lymphoma (168). In PBC, CXCL12 activates B cells through CXCR4 signaling and modulates the production of pro-fibrotic cytokines in the liver. Experimental knockdown of CXCL12 or pharmacologic blockade of the CXCL12/CXCR4 axis reduces hepatic B-cell infiltration and mitigates liver fibrosis (169).

The CXCL9/CXCL10/CXCL11-CXCR3 axis promotes Th1 cell activation and induces IFN-γ expression, thereby promoting T lymphocyte migration to inflammatory sites. In the MSGs of patients with pSS, expression of CXCL9, CXCL10, and CXCL11 is markedly upregulated and strongly correlates with lymphocyte focus scores and the severity of glandular dysfunction (170). In patients with PBC, serum levels of CXCL9 and CXCL10 are significantly elevated, accompanied by an increased frequency of CXCR3⁺ cells in both the liver and peripheral blood, which enhances effector T cell recruitment to affected tissues (171). In PBC animal models, suppression of CXCL10 expression attenuates hepatic inflammation and fibrosis, while CXCR3 deficiency mitigates inflammatory progression (175). These findings indicate that targeting the CXCL9/CXCL10/CXCL11-CXCR3 axis may represent a promising therapeutic strategy for PBC.

The CCL21/CCR7 axis regulates the initiation of immune responses and maintains immune tolerance. This pathway mediates the chemotactic migration of lymphocytes into MSGs and represents a critical factor in lymphoma development among pSS patients. In PBC, CCL21 is strongly expressed within lymphoid aggregates of the portal tracts (173, 176). By enhancing lymphocyte activation and proliferation around damaged bile ducts and glands, the CCL21/CCR7 axis markedly increases the extent of lymphocytic infiltration. In pSS, elevated CCL21 levels are associated with abnormal ESR and RF, while activated B cells produce higher levels of IgG, anti-SSA, and anti-SSB antibodies, collectively resulting in elevated serum autoantibody titers (168, 172).

6 Targeted drug similarities

In clinical practice, the management of patients with both pSS and PBC requires a comprehensive evaluation of disease status, with personalized therapeutic strategies tailored to disease activity and the extent of systemic involvement.

Current clinical approaches to pSS primarily target local manifestations such as xerostomia and keratoconjunctivitis sicca. Localized therapies are frequently employed to alleviate symptoms, reduce tissue injury, and mitigate systemic dysfunction. In patients with parotid gland enlargement or severe organ involvement, corticosteroids (e.g., prednisone, methylprednisolone) and immunosuppressive agents (e.g., cyclophosphamide, hydroxychloroquine) can effectively suppress inflammatory responses, though regular clinical monitoring is essential throughout treatment. Traditional Chinese medicine provides a multi-targeted therapeutic strategy, acting through diverse pathways. Tripterygium glycosides, for example, possess anti-inflammatory and immunomodulatory properties, providing multiple therapeutic targets and demonstrating promising benefits in pSS management. However, their long-term efficacy and safety remain to be fully established (177).

The therapeutic goals for PBC are to alleviate cholestatic symptoms, control hepatic inflammation, delay the progression of liver fibrosis, and prevent complications of end-stage liver disease. Ursodeoxycholic acid (UDCA), the current first-line therapy, promotes bile flow by facilitating anion exchange and bile alkalinization, thereby reducing bile acid toxicity, intrahepatic cholestasis, and bile duct injury. Beyond its choleretic effects, UDCA exerts immunomodulatory effects by stabilizing mitochondrial membranes, suppressing IFN-γ production, and improving the hepatic immune microenvironment, which collectively attenuate autoimmune-mediated damage. Nevertheless, approximately 40% of patients exhibit an insufficient response to UDCA, with its therapeutic efficacy markedly reduced in advanced stages of PBC (178).

Localized therapies for pSS and PBC provide only symptomatic relief of glandular dysfunction and fail to address the underlying fundamental immune dysregulation underlying these diseases, including abnormal immune cell proliferation and differentiation. In recent years, extensive efforts have been directed toward targeting immune regulatory pathways and modulating both the quantity and function of immune cells, yielding significant progress. In this review, we systematically classify and summarize the major targeted therapeutic agents and their related signaling pathways in the clinical management of pSS and PBC, with detailed information presented in Table 3 and Figure 2.

Table 3

Table 3. Clinical Therapeutic Targets, Drugs, and Mechanisms for pSS and PBC.

Figure 2

Figure 2. Drugs targeting major pathways and receptors in the pathophysiology of pSS and PBC. The interaction between T and B cells is a crucial event in the pathogenesis of pSS and PBC. Therapeutic agents that act on lymphocyte surface receptors or related signaling pathways can attenuate immune-mediated attacks against self-antigens, thereby providing clinical benefit. Cytokines such as ILs, IFNs, and TNFs activate the JAK/STAT and PPAR pathways, driving lymphocyte survival, differentiation, and antibody production. JAK inhibitors and PPAR agonists suppress aberrant lymphocyte proliferation and differentiation while improving tissue lipid metabolism. The mTOR pathway regulates protein synthesis, cellular metabolism, and growth; its inhibition suppresses Tfh cell differentiation, restores the Tfr/Tfh balance, and alleviates tissue inflammation. Interleukin inhibitors modulate T-cell subset function, dampen hyperactive immune responses, and restore immune homeostasis, thereby mitigating autoimmune injury in conditions such as pSS and PBC. Additional therapeutic targets include co-stimulatory molecules. By blocking CD80/CD86 binding to CD28 on T cells, agents prevent co-stimulatory signaling, thereby limiting T-cell activation, proliferation, and cytokine secretion. The CD40/CD40L axis contributes to sustained immune activation and antibody production, processes central to germinal center formation. Targeting ICOSL reduces both B-cell and Th17 cell activation. BAFF and APRIL act synergistically to promote B-cell survival, proliferation, and activation, regulate peripheral B-cell homeostasis, and maintain humoral immunity. Inhibition of BAFF signaling effectively suppresses B-cell activation and autoantibody production. Anti-CD20 therapies enhance cytotoxic responses against B lymphocytes, resulting in their depletion. Finally, CAR-T cell therapy, by engineering autologous T cells to recognize and eliminate B cells, represents an innovative approach to reducing B-cell numbers and suppressing their pathogenic activity. pSS, primary Sjogren’s syndrome; PBC, primary biliary cholangitis; JAK/STAT, Janus kinase-signal transducer and activator of transcription; PPAR, peroxisome proliferator-activated receptor; mTOR, mechanistic target of rapamycin; Tfr, follicular regulatory T cells; Tfh, T follicular helper; CD, cluster of differentiation; ICOSL, inducible T-cell co-stimulator ligand; Th, T helper; BAFF, B-cell activating factor; APRIL, a proliferation-inducing ligand; CAR-T, Chimeric Antigen Receptor T-cell.

6.1 Therapy targeted pathways and receptors

6.1.1 Targeting the JAK/STAT signaling pathway

The JAK/STAT signaling pathway is a critical intracellular cascade of protein interactions. Upon cytokine stimulation, Janus kinases (JAKs) phosphorylate signal transducers and activators of transcription (STATs), leading to their dimerization and subsequent translocation into the nucleus, where they regulate the expression of specific target genes. In patients with pSS and PBC, aberrant activation of the JAK/STAT pathway, particularly through IFN-I-mediated signaling, contributes to the heightened activation of both T and B lymphocytes. Targeted therapies aimed at inhibiting this pathway have shown encouraging therapeutic efficacy in the treatment of these diseases, positioning the JAK/STAT axis as a promising target for immunomodulatory intervention.

Baricitinib, a selective JAK1/2 inhibitor, exerts immunomodulatory effects by inhibiting JAK enzymatic activity, thereby reducing immune cell proliferation and activation, as well as autoantibody production. Exerts immunomodulatory effects by inhibiting JAK enzymatic activity, thereby reducing immune cell proliferation and activation, as well as autoantibody production. These mechanisms contribute to the therapeutic improvement of autoimmune diseases. In pSS, a preliminary study indicates that baricitinib can inhibit IFN-γ and CXCL10 expression in MSGs, significantly decrease ESSDAI scores, and alleviate arthritis and cutaneous manifestations. Serum IgG levels and ESR also declined during treatment, with the exception of the 3rd month (182). In PBC, baricitinib treatment is associated with a markedly faster reduction in serum ALP, alongside improvement in pruritus and depressive symptoms. Liver histological analyses further revealed decreased hepatic inflammation and fibrosis, indicating superior efficacy compared with conventional therapies such as UDCA (183). Currently, a phase II randomized, double-blind, placebo-controlled proof-of-concept trial (NCT03742973) is underway to further assess the therapeutic potential of baricitinib in PBC.

6.1.2 Targeting the mTOR signaling pathway

The mechanistic target of rapamycin (mTOR) signaling pathway plays a central role in intracellular signal transduction. By activating mTOR and its upstream and downstream effectors, this pathway regulates protein synthesis and cellular metabolism, thereby governing cell growth and proliferation.

Sirolimus, a potent mTORC1 inhibitor, exerts its immunomodulatory effects by restricting mTORC1 activation, which suppresses the differentiation of Tfh cells and restores the balance between Tfr and Tfh cells. This subsequently attenuates B-cell activation and alleviates tissue inflammation. In patients with pSS, mTOR inhibition effectively suppresses B-cell proliferation and immunoglobulin production, mitigating immune-mediated inflammation and facilitating the restoration of lacrimal gland function (184). In experimental SS models, sirolimus downregulated mTOR pathway activity, reduced the expression of inflammatory cytokines and chemokines, and inhibited Th17 cell differentiation as well as IL-17 secretion. These effects collectively resulted in substantial reductions in SG lymphocyte infiltration and inflammation (215). In zebrafish mutants, hyperactivation of the PI3K/AKT/mTOR pathway in hepatic tissue has been linked to PBC-like lesions, and sirolimus treatment partially ameliorated these pathological features, suggesting a potential therapeutic role (185). However, clinical and preclinical data regarding mTOR as a therapeutic target in PBC remain limited and warrant further investigation.

6.1.3 Targeting the interleukin pathway

Ustekinumab is a monoclonal antibody that targets IL-12 and IL-23 by binding to their shared p40 subunit, thereby preventing cytokine-receptor interactions, suppressing IFN-γ production, and attenuating Th1/Th17 responses. In a proof-of-concept clinical trial for PBC, 28 weeks of ustekinumab therapy led to a moderate reduction in serum ALP levels (187). However, its precise role in modulating the immunopathology of PBC remains to be fully elucidated. Clinically, ustekinumab has also demonstrated significant improvement in joint involvement among psoriasis patients with concomitant pSS. Notably, no pSS-related signs or symptoms were observed during long-term follow-up (188). Furthermore, a pilot study (NCT04093531) showed reductions in both ESSPRI and ESSDAI scores after 24 weeks of treatment. Currently, a Phase I open-label trial is enrolling participants to further assess ustekinumab in pSS, and forthcoming data are expected to provide deeper insights into its therapeutic potential.

Low-dose interleukin-2 (LD-IL-2) therapy holds significant promise in the treatment of pSS and PBC. In SS murine models, LD-IL-2 administration effectively restored the proportion of Tregs in the spleen and cervical lymph nodes (216). Clinical trials in pSS patients demonstrated that LD-IL-2 therapy effectively increases peripheral Treg numbers, rebalances the Th17/Treg ratio, reduces pro-inflammatory cytokine levels, and improves the local immune microenvironment. Additionally, LD-IL-2 therapy has also shown clinical benefits in correcting thrombocytopenia and leukopenia. However, LD-IL-2 failed to reduce autoantibody levels (189). In PBC murine models, LD-IL-2 treatment was found to restore Th17/Treg balance, attenuate inflammatory infiltration in the portal area, and alleviate bile duct injury (217). Despite these encouraging findings, the optimal dosing strategy and safety profile of LD-IL-2 therapy in patients with PBC remain under investigation in ongoing preclinical and early-phase clinical studies.

6.1.4 Targeting the PPAR

Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear receptors that regulate intracellular lipid and energy metabolism, and they also exhibit significant anti-inflammatory properties. The PPAR family includes PPAR-α and PPAR-γ, both of which play critical roles in modulating immune responses in T and B lymphocytes. PPAR-α regulates immune activity by antagonizing NF-κB and IL-1β signaling pathways in T cells, whereas PPAR-γ suppresses T cell proliferation and differentiation by preventing NFAT and NF-κB binding to the IL-2 promoter. In addition, PPAR-γ contributes to the regulation of B cell homeostasis by promoting apoptosis via cytotoxic mechanisms, effectively limiting B cell proliferation. Notably, PPAR-α and PPAR-γ regulate IFN-γ and IL-17 production in T cells in a sex-specific manner. This sexually dimorphic regulation may partially account for the higher prevalence of T cell–mediated autoimmune diseases observed in females (218).

Fenofibrate, a commonly used PPAR-α agonist, regulates lipid metabolism and alleviates chronic inflammation associated with lipid accumulation. Owing to its anti-inflammatory and metabolic effects, fenofibrate has therapeutic potential in various autoimmune diseases. In patients with PBC, fenofibrate has been reported to lower intrahepatic bile acid concentrations, thereby reducing bile acid-induced cytotoxicity toward cholangiocytes. It also improves serum ALP levels and suppresses hepatic and biliary inflammation, while maintaining a favorable clinical safety profile (193, 219). It has also been shown to reduce IgM levels and AMA antibody titers (193, 220). Preclinical studies further demonstrate that fenofibrate effectively suppresses Th1/Th17 responses in SS mouse models, increases both the number and functional activity of Tregs, and ameliorates histopathological features of autoimmune sialadenitis. These encouraging findings highlight its potential as a novel therapeutic approach for pSS (192). However, the clinical application of fenofibrate in pSS remains insufficiently validated, with limited trial data available to confirm its efficacy as a standalone therapy.

6.2 Therapeutic pathways for targeting lymphocytes

6.2.1 Targeting T lymphocytes

Abatacept is a humanized fusion protein composed of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the Fc region of human IgG1. By binding to CD80 and CD86 expressed on antigen-presenting cells, it blocks T-cell costimulatory signaling. This mechanism effectively reduces T-cell activation and proliferation, reprograms T-cell function, and ultimately attenuates T-cell-mediated immune response.

In a clinical trial involving patients with RA, abatacept demonstrated the potential to improve salivary and tear secretion, providing a theoretical rationale for its application in the treatment of pSS (221). In a subsequent study of fifteen patients with pSS, abatacept reduced circulating Tfh and Treg cell populations, decreased serum levels of IL-21, CXCL13, and CXCL1, inhibited lymphocyte migration, and attenuated inflammatory infiltration. It also decreased PC numbers and reduced serum anti-SSA and anti-SSB antibody levels, thereby suppressing overall disease activity (200). Clinical investigations in early-stage pSS further showed that abatacept improved disease activity, laboratory parameters, and fatigue; however, its therapeutic benefits appeared less pronounced in individuals with moderate to severe disease activity (201). A single-center phase III trial reported that 48 weeks of abatacept treatment alleviated pSS symptoms, improved dry eye manifestations, significantly reduced disease activity, downregulated T-cell activation markers, and diminished lymphocytic infiltration (222). In contrast, another investigation failed to demonstrate symptomatic improvement in pSS patients (223). These findings highlight the need for additional randomized controlled trials to comprehensively assess the efficacy of abatacept in pSS and to clarify its effects on specific disease manifestations.

Abatacept has also been extensively studied as a potential therapeutic agent for PBC. Preclinical studies demonstrated that it reduced intrahepatic T-cell infiltration and alleviated BECs injury, although it failed to decrease serum levels of autoantibodies, particularly AMA (224). In clinical settings, combination therapy with sulfasalazine and abatacept normalized ALP and γ-GT levels in PBC patients, accompanied by histological evidence of reduced portal and periductal inflammation on liver biopsy (202). However, in a randomized controlled trial involving 22 PBC patients, only one participant (6.3%) achieved ALP normalization after 24 weeks of abatacept monotherapy, while no significant clinical improvements were observed in the remaining subjects (225). Mechanistically, abatacept acts primarily by inhibiting T-cell co-stimulatory signaling, but it does not effectively suppress terminally differentiated T or B cells, particularly CD8⁺ T cells. Consequently, neither preclinical models nor clinical trials have demonstrated consistent reductions in autoantibody production. These findings suggest that the efficacy of abatacept in PBC remains uncertain and warrants further clinical validation through larger, well-designed studies.

6.2.2 Targeting lymphocyte activating factor

B-cell activation constitutes a pivotal mechanism in the shared immunopathogenesis of pSS and PBC. Elevated BAFF levels are strongly associated with both diseases, sustaining autoantibody production by promoting plasma cell survival.

Belimumab, a monoclonal antibody that targets BAFF, exerts its immunomodulatory effects by inhibiting B-cell maturation and reducing B-cell activation. Clinical studies have shown that belimumab significantly improves the pSS disease activity index, alleviates subjective symptoms such as dryness, pain, and fatigue, and reduces parotid gland swelling and lymphadenopathy. These clinical improvements are accompanied by a sustained decline in biomarkers associated with B-cell activation (203, 204). In a reported PBC case, belimumab has been investigated in limited clinical settings. In one case report, treatment with belimumab successfully reduced serum IgM levels; however, no improvement was observed in the degree of cholestasis or hepatic fibrosis (205). Although BAFF-targeting therapies such as belimumab show considerable promise for the management of PBC, no agents have yet received regulatory approval for this indication. Further randomized controlled trials are required to establish their efficacy and define their role in clinical practice.

Telitacicept, a novel TACI-Fc fusion protein, suppresses B-cell development and maturation by blocking both BAFF and APRIL signaling pathways. By preventing the differentiation of mature B cells into antibody-secreting PCs, it effectively reduces the secretion of pathogenic autoantibodies. In a multicenter, randomized, double-blind, placebo-controlled phase II trial in pSS (NCT04078386), telitacicept significantly improved ESSDAI scores and decreased serum autoantibody levels at weeks 12 and 24. However, despite these objective improvements in disease activity, patient-reported symptoms such as fatigue, pain, and dryness did not show meaningful relief (208). More recently, telitacicept has demonstrated encouraging results in additional clinical studies for pSS and has progressed to a phase III clinical trial (CTR20223429). Notably, in a case involving a patient with pSS and comorbid PBC who was unresponsive to combined corticosteroid and immunosuppressive therapy, telitacicept treatment resulted in marked improvements in liver function parameters and reduced corticosteroid dependence. Collectively, these findings highlight telitacicept as a promising therapeutic candidate for both pSS and PBC.

6.2.3 Targeting B-lymphocytes

Rituximab is a monoclonal antibody targeting the CD20 surface antigen expressed on pre-B and mature B lymphocytes. By binding to CD20, rituximab initiates B-cell depletion through multiple cytotoxic mechanisms, including complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, leading to the depletion of peripheral B lymphocytes.

Early clinical trials demonstrated that rituximab effectively alleviates certain early symptoms of pSS, such as fatigue and parotid gland enlargement. However, its effects on pSS symptoms remain inconsistent, and its long-term efficacy is still uncertain (211). More recent studies have shown that repeated rituximab infusions and extended treatment duration can effectively reduce peripheral immune activation, limit B-cell recruitment into the MSGs, and inhibit the formation of eGCs (226). Despite successful B-cell depletion, immunoglobulin-producing cells persist in the MSGs of pSS patients following rituximab treatment, and B-cell populations remain detectable in the glands (227). Recognizing the limitations of rituximab monotherapy, combination strategies, such as co-administration of rituximab (anti-CD20) with belimumab (anti-BAFF), are currently under investigation. This combined approach has achieved profound and durable depletion of CD20⁺ and CD19⁺ B-cell subsets in both MSGs and peripheral blood, representing a potentially more effective therapeutic strategy (228).

Rituximab is the first biologic agent introduced for the treatment of PBC. In a randomized trial involving 57 patients with PBC, three months of rituximab infusion led to a significant reduction in serum ALP levels; however, no meaningful improvement in fatigue was observed (212). Treatment also lowered plasma IgM and IgG concentrations and reduced AMA secretion, although overall improvements in hepatic biochemical parameters remained modest. Importantly, these effects were transient, suggesting that repeated administration may be necessary to sustain therapeutic efficacy (213, 214). In preclinical PBC models, combination therapy targeting both BAFF and CD20 significantly reduced B-cell populations in peripheral blood and hepatic tissues, while attenuating portal inflammation and bile duct injury-highlighting its potential therapeutic value (229). Overall, rituximab demonstrates therapeutic potential in both pSS and PBC, particularly in combination regimens. Nevertheless, B-cell depletion alone may be insufficient to restore glandular function, and the durability and clinical applicability of rituximab therapy remain to be further validated.

With the increasing understanding of pSS pathogenesis, a growing number of therapeutic agents targeting lymphocyte subsets and cell surface receptors are under active investigation. Ianalumab, a dual B-cell depleting and BAFF receptor-blocking antibody; epratuzumab, an inhibitor of B-cell activation; and iscalimab, a monoclonal antibody that suppresses CD40-CD40L-mediated co-stimulatory signaling between T and B cells, have all demonstrated encouraging therapeutic effects in clinical studies. In addition, chimeric antigen receptor T (CAR-T) cell therapy, an emerging immunotherapeutic approach, has been applied in refractory pSS. This strategy involves engineering autologous T cells to express chimeric antigen receptors directed against CD19, enabling selective recognition and elimination of B cells. In pSS, CAR-T therapy primarily functions to deplete B cells and restore immune homeostasis. Looking forward, CAR-T therapy is expected to be further explored in PBC, where it may provide a more targeted therapeutic option tailored to specific patient populations and disease phenotypes, with the potential to correct autoimmune dysregulation at its root.

7 Conclusions

Both pSS and PBC are autoimmune diseases that share striking similarities in their underlying pathogenic mechanisms. Genetic predisposition, X chromosome-linked factors, sex hormones, viral infections, and environmental triggers collectively contribute to the initiation or amplification of autoimmune responses, ultimately leading to impaired glandular and liver tissue.

From an immunological perspective, pSS and PBC are closely interconnected, displaying common autoantibody profiles, including ACA. Histologically, both conditions are characterized by comparable patterns of lymphocytic aggregation and infiltration surrounding glands and ducts.

In the tissue immune microenvironment, both pSS and PBC display similar patterns of epithelial injury and lymphocytic infiltration. Hypoxia and senescence of epithelial cells promote aberrant cell death and facilitate their role as autoantigen-presenting cells, while dysregulated fibroblast activation accelerates inflammation and fibrosis. Disbalance between T and B lymphocytes, particularly the excessive activation of B cells, emerges as a pivotal driver of autoimmunity. Elevated levels of IL-17 and IL-23 enhance Th17 cell function and abnormal B-cell activation, whereas increased IFN and TNF expression further stimulate antigen-presenting cells and B lymphocytes, amplifying autoantibody production. Additionally, upregulation of chemokines such as CXCL9, CXCL10, CXCL11, CXCL12, and CCL21 promotes lymphocyte infiltration into glandular tissues and fosters the formation of ectopic germinal centers. Collectively, these immunopathological processes represent key shared mechanisms driving disease progression in both conditions.

Therapeutically, the shared pathogenic mechanisms of pSS and PBC provide opportunities for common treatment strategies. Targeted agents against the JAK/STAT pathway (tofacitinib and baricitinib), the mTOR signaling pathway (sirolimus), the IL-12/23 receptor (ustekinumab), and PPAR agonists (fenofibrate) have all demonstrated favorable clinical outcomes. Lymphocyte-directed approaches, including abatacept, which modulates T-cell activation, and rituximab, which depletes B cells, have also shown promising efficacy; however, further clinical data are needed to confirm their long-term benefits. BAFF-driven B-cell activation plays a pivotal role in both diseases. Inhibitors of BAFF, such as telitacicept and belimumab, have significantly improved clinical manifestations in pSS, but their effects on hepatic histopathology in PBC remain to be validated in future clinical studies.

In summary, we describe the common pathways and means of clinical treatment for patients with pSS and PBC by dissecting the serologic and histologic similarities between pSS and PBC. In the future, by delving into the pathogenesis of these two diseases, we may find more effective treatments to provide more effective and personalized therapies for treating patients and improving their quality of life.

Author contributions

KY: Writing – original draft, Investigation, Conceptualization, Writing – review & editing. XY: Conceptualization, Writing – original draft, Writing – review & editing, Investigation. DL: Supervision, Conceptualization, Writing – review & editing. CT: Supervision, Writing – review & editing. XW: Funding acquisition, Writing – review & editing, Supervision.

Funding

The authors declare financial support was received for the research and/or publication of this article. This work was supported by National Natural Science Foundation of China (NO.82374402), and by School-level scientific research personnel special project of Zhejiang Chinese Medical University (2024RCZXZK55).

Acknowledgments

Figure 1 is provided by the company of Shenzhen Weikemo Technology Co., Ltd.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American college of rheumatology/European league against rheumatism classification criteria for primary sjögren's syndrome: A consensus and data-Driven methodology involving three international patient cohorts. Arthritis Rheumatol (Hoboken NJ). (2017) 69:35–45. doi: 10.1002/art.39859

PubMed Abstract | Crossref Full Text | Google Scholar

2. Gao J, Qiao L, and Wang B. Primary biliary cirrhosis is a generalized autoimmune epithelitis. Int J Mol Sci. (2015) 16:6432–46. doi: 10.3390/ijms16036432

PubMed Abstract | Crossref Full Text | Google Scholar

3. Bowlus CL and Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev. (2014) 13:441–4. doi: 10.1016/j.autrev.2014.01.041

PubMed Abstract | Crossref Full Text | Google Scholar

4. Qian Q, Wu Y, Cui N, Li Y, Zhou Y, Li Y, et al. Epidemiologic and genetic associations between primary biliary cholangitis and extrahepatic rheumatic diseases. J Autoimmun. (2024) 148:103289. doi: 10.1016/j.jaut.2024.103289

PubMed Abstract | Crossref Full Text | Google Scholar

5. Liu B, Zhang FC, Zhang ZL, Zhang W, and Gao LX. Interstitial lung disease and sjögren's syndrome in primary biliary cirrhosis: A causal or casual association? Clin Rheumatol. (2008) 27:1299–306. doi: 10.1007/s10067-008-0917-x

PubMed Abstract | Crossref Full Text | Google Scholar

6. De Santis M, Crotti C, and Selmi C. Liver abnormalities in connective tissue diseases. Best Pract Res Clin Gastroenterol. (2013) 27:543–51. doi: 10.1016/j.bpg.2013.06.016

PubMed Abstract | Crossref Full Text | Google Scholar

7. Hatzis GS, Fragoulis GE, Karatzaferis A, Delladetsima I, Barbatis C, and Moutsopoulos HM. Prevalence and longterm course of primary biliary cirrhosis in primary sjögren's syndrome. J Rheumatol. (2008) 35:2012–6.

PubMed Abstract | Google Scholar

8. Wang N, Zhou Y, Li H, Chen L, and Li Q. Primary biliary cholangitis and sjogren's syndrome: bi-directional mendelian randomization analysis. Eur Rev Med Pharmacol Sci. (2024) 28:3556–65. doi: 10.26355/eurrev_202405_36292

PubMed Abstract | Crossref Full Text | Google Scholar

9. Corpechot C, Chrétien Y, Chazouillères O, and Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. (2010) 53:162–9. doi: 10.1016/j.jhep.2010.02.019

PubMed Abstract | Crossref Full Text | Google Scholar

10. Kuo CF, Grainge MJ, Valdes AM, See LC, Luo SF, Yu KH, et al. Familial risk of sjögren's syndrome and co-aggregation of autoimmune diseases in affected families: A nationwide population study. Arthritis Rheumatol (Hoboken NJ). (2015) 67:1904–12. doi: 10.1002/art.39127

PubMed Abstract | Crossref Full Text | Google Scholar

11. Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, Underhill JA, et al. Hla class ii alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study. Hepatol (Baltimore Md). (2006) 44:667–74. doi: 10.1002/hep.21316

PubMed Abstract | Crossref Full Text | Google Scholar

12. Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, and Anaya JM. Hla and sjögren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. (2012) 11:281–7. doi: 10.1016/j.autrev.2011.10.002

PubMed Abstract | Crossref Full Text | Google Scholar

13. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with sjögren's syndrome. Nat Genet. (2013) 45:1284–92. doi: 10.1038/ng.2792

PubMed Abstract | Crossref Full Text | Google Scholar

14. Webb GJ, Siminovitch KA, and Hirschfield GM. The immunogenetics of primary biliary cirrhosis: A comprehensive review. J Autoimmun. (2015) 64:42–52. doi: 10.1016/j.jaut.2015.07.004

PubMed Abstract | Crossref Full Text | Google Scholar

15. Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, et al. In primary sjögren's syndrome, hla class ii is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis rheumatism. (2003) 48:2240–5. doi: 10.1002/art.11103

PubMed Abstract | Crossref Full Text | Google Scholar

16. Thorlacius GE, Björk A, and Wahren-Herlenius M. Genetics and epigenetics of primary sjögren syndrome: implications for future therapies. Nat Rev Rheumatol. (2023) 19:288–306. doi: 10.1038/s41584-023-00932-6

PubMed Abstract | Crossref Full Text | Google Scholar

17. Donaldson P, Agarwal K, Craggs A, Craig W, James O, and Jones D. Hla and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut. (2001) 48:397–402. doi: 10.1136/gut.48.3.397

PubMed Abstract | Crossref Full Text | Google Scholar

18. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis associated with hla, il12a, and il12rb2 variants. New Engl J Med. (2009) 360:2544–55. doi: 10.1056/NEJMoa0810440

PubMed Abstract | Crossref Full Text | Google Scholar

19. Xiang B, Deng C, Qiu F, Li J, Li S, Zhang H, et al. Single cell sequencing analysis identifies genetics-modulated ormdl3(+) cholangiocytes having higher metabolic effects on primary biliary cholangitis. J nanobiotechnology. (2021) 19:406. doi: 10.1186/s12951-021-01154-2

PubMed Abstract | Crossref Full Text | Google Scholar

20. Invernizzi P, Selmi C, Poli F, Frison S, Floreani A, Alvaro D, et al. Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. Hepatol (Baltimore Md). (2008) 48:1906–12. doi: 10.1002/hep.22567

PubMed Abstract | Crossref Full Text | Google Scholar

21. Hewagama A, Patel D, Yarlagadda S, Strickland FM, and Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun. (2009) 10:509–16. doi: 10.1038/gene.2009.12

PubMed Abstract | Crossref Full Text | Google Scholar

22. Gerussi A, Cristoferi L, Carbone M, Asselta R, and Invernizzi P. The immunobiology of female predominance in primary biliary cholangitis. J Autoimmun. (2018) 95:124–32. doi: 10.1016/j.jaut.2018.10.015

PubMed Abstract | Crossref Full Text | Google Scholar

23. Liu K, Kurien BT, Zimmerman SL, Kaufman KM, Taft DH, Kottyan LC, et al. X chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47,Xxx in systemic lupus erythematosus and sjögren's syndrome. Arthritis Rheumatol (Hoboken NJ). (2016) 68:1290–300. doi: 10.1002/art.39560

PubMed Abstract | Crossref Full Text | Google Scholar

24. Palmer AK and Tan IJ. Synergistic effects of extra X chromosome on development of systemic lupus erythematosus and sjögren disease in klinefelter and triple X syndrome: A retrospective cohort study. ACR Open Rheumatol. (2025) 7:e11778. doi: 10.1002/acr2.11778

PubMed Abstract | Crossref Full Text | Google Scholar

25. Ozcelik T. X chromosome inactivation and female predisposition to autoimmunity. Clin Rev Allergy Immunol. (2008) 34:348–51. doi: 10.1007/s12016-007-8051-0

PubMed Abstract | Crossref Full Text | Google Scholar

26. Mitchell MM, Lleo A, Zammataro L, Mayo MJ, Invernizzi P, Bach N, et al. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics. (2011) 6:95–102. doi: 10.4161/epi.6.1.13405

PubMed Abstract | Crossref Full Text | Google Scholar

27. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet (London England). (2004) 363:533–5. doi: 10.1016/s0140-6736(04)15541-4

PubMed Abstract | Crossref Full Text | Google Scholar

28. Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatol (Baltimore Md). (2007) 46:456–62. doi: 10.1002/hep.21696

PubMed Abstract | Crossref Full Text | Google Scholar

29. Asselta R, Paraboschi EM, Gerussi A, Cordell HJ, Mells GF, Sandford RN, et al. X chromosome contribution to the genetic architecture of primary biliary cholangitis. Gastroenterology. (2021) 160:2483–95.e26. doi: 10.1053/j.gastro.2021.02.061

PubMed Abstract | Crossref Full Text | Google Scholar

30. Konttinen YT, Fuellen G, Bing Y, Porola P, Stegaev V, Trokovic N, et al. Sex steroids in sjögren's syndrome. J Autoimmun. (2012) 39:49–56. doi: 10.1016/j.jaut.2012.01.004

PubMed Abstract | Crossref Full Text | Google Scholar

31. Blatkiewicz M, Sielatycka K, Piotrowska K, and Kilańczyk E. Dhea and its metabolites reduce the cytokines involved in the inflammatory response and fibrosis in primary biliary cholangitis. Int J Mol Sci. (2023) 24:5301. doi: 10.3390/ijms24065301

PubMed Abstract | Crossref Full Text | Google Scholar

32. Ishimaru N, Saegusa K, Yanagi K, Haneji N, Saito I, and Hayashi Y. Estrogen deficiency accelerates autoimmune exocrinopathy in murine sjögren's syndrome through fas-mediated apoptosis. Am J Pathol. (1999) 155:173–81. doi: 10.1016/s0002-9440(10)65111-5

PubMed Abstract | Crossref Full Text | Google Scholar

33. Bae HR, Leung PS, Tsuneyama K, Valencia JC, Hodge DL, Kim S, et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatol (Baltimore Md). (2016) 64:1189–201. doi: 10.1002/hep.28641

PubMed Abstract | Crossref Full Text | Google Scholar

34. Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, and Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Internal Med (Tokyo Japan). (2011) 50:1–10. doi: 10.2169/internalmedicine.50.4462

PubMed Abstract | Crossref Full Text | Google Scholar

35. Jin L, Dai M, Li C, Wang J, and Wu B. Risk factors for primary sjögren's syndrome: A systematic review and meta-analysis. Clin Rheumatol. (2023) 42:327–38. doi: 10.1007/s10067-022-06474-8

PubMed Abstract | Crossref Full Text | Google Scholar

36. Kaplan MJ and Ike RW. The liver is a common non-exocrine target in primary sjögren's syndrome: A retrospective review. BMC Gastroenterol. (2002) 2:21. doi: 10.1186/1471-230x-2-21

PubMed Abstract | Crossref Full Text | Google Scholar

37. Saito I, Servenius B, Compton T, and Fox RI. Detection of epstein-barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with sjogren's syndrome. J Exp Med. (1989) 169:2191–8. doi: 10.1084/jem.169.6.2191

PubMed Abstract | Crossref Full Text | Google Scholar

38. Morshed SA, Nishioka M, Saito I, Komiyama K, and Moro I. Increased expression of epstein-barr virus in primary biliary cirrhosis patients. Gastroenterologia Japonica. (1992) 27:751–8. doi: 10.1007/bf02806528

PubMed Abstract | Crossref Full Text | Google Scholar

39. Yang L, Pu J, Cai F, Zhang Y, Gao R, Zhuang S, et al. Chronic epstein-barr virus infection: A potential junction between primary sjögren's syndrome and lymphoma. Cytokine. (2023) 168:156227. doi: 10.1016/j.cyto.2023.156227

PubMed Abstract | Crossref Full Text | Google Scholar

40. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American college of rheumatology classification criteria for sjögren's syndrome: A data-driven, expert consensus approach in the sjögren's international collaborative clinical alliance cohort. Arthritis Care Res. (2012) 64:475–87. doi: 10.1002/acr.21591

PubMed Abstract | Crossref Full Text | Google Scholar

41. Selmi C, Bowlus CL, Gershwin ME, and Coppel RL. Primary biliary cirrhosis. Lancet (London England). (2011) 377:1600–9. doi: 10.1016/s0140-6736(10)61965-4

PubMed Abstract | Crossref Full Text | Google Scholar

42. Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, et al. Association of combined anti-ro52/trim21 and anti-ro60/ssa antibodies with increased sjögren disease severity through interferon pathway activation. Arthritis Rheumatol (Hoboken NJ). (2024) 76:751–62. doi: 10.1002/art.42789

PubMed Abstract | Crossref Full Text | Google Scholar

43. Kamounah S, Wei F, Park JK, Song YW, Chia D, Wong DTW, et al. Seronegative patients with primary sjögren's syndrome and non-pss sicca test positive for anti-ssa/ro52 and -ro60 in saliva. Biochim Biophys Acta Mol basis Dis. (2024) 1870:167168. doi: 10.1016/j.bbadis.2024.167168

PubMed Abstract | Crossref Full Text | Google Scholar

44. Retamozo S, Akasbi M, Brito-Zerón P, Bosch X, Bove A, Perez-de-Lis M, et al. Anti-ro52 antibody testing influences the classification and clinical characterisation of primary sjögren's syndrome. Clin Exp Rheumatol. (2012) 30:686–92.

PubMed Abstract | Google Scholar

45. Armağan B, Robinson SA, Bazoberry A, Perin J, Grader-Beck T, Akpek EK, et al. Antibodies to both ro52 and ro60 for identifying sjögren's syndrome patients best suited for clinical trials of disease-modifying therapies. Arthritis Care Res. (2022) 74:1559–65. doi: 10.1002/acr.24597

PubMed Abstract | Crossref Full Text | Google Scholar

46. Liu J, Feng J, Zhu F, Chen Y, Chen J, Li Y, et al. Analysis of the relationships between interferon-stimulated genes and anti-ssa/ro 60 antibodies in primary sjögren's syndrome patients via multiomics and machine learning methods. Int Immunopharmacol. (2025) 144:113652. doi: 10.1016/j.intimp.2024.113652

PubMed Abstract | Crossref Full Text | Google Scholar

47. Hu C, Deng C, Song G, Zhang W, Zhang S, Li X, et al. Prevalence of autoimmune liver disease related autoantibodies in chinese patients with primary biliary cirrhosis. Digestive Dis Sci. (2011) 56:3357–63. doi: 10.1007/s10620-011-1756-1

PubMed Abstract | Crossref Full Text | Google Scholar

48. Zhu YJ, Li J, Liu YG, Jiang Y, Cheng XJ, Han X, et al. Role of biochemical markers and autoantibodies in diagnosis of early-stage primary biliary cholangitis. World J Gastroenterol. (2023) 29:5075–81. doi: 10.3748/wjg.v29.i34.5075

PubMed Abstract | Crossref Full Text | Google Scholar

49. Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, and Mariette X. Anticentromere antibodies identify patients with sjögren's syndrome and autoimmune overlap syndrome. J Rheumatol. (2007) 34:2253–8.

PubMed Abstract | Google Scholar

50. Miyawaki S, Asanuma H, Nishiyama S, and Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol. (2005) 32:1488–94.

PubMed Abstract | Google Scholar

51. Kajio N, Takeshita M, Suzuki K, Kaneda Y, Yamane H, Ikeura K, et al. Anti-centromere antibodies target centromere-kinetochore macrocomplex: A comprehensive autoantigen profiling. Ann rheumatic Dis. (2021) 80:651–9. doi: 10.1136/annrheumdis-2020-218881

PubMed Abstract | Crossref Full Text | Google Scholar

52. Nakamura H, Kawakami A, Hayashi T, Iwamoto N, Okada A, Tamai M, et al. Anti-centromere antibody-seropositive sjögren's syndrome differs from conventional subgroup in clinical and pathological study. BMC musculoskeletal Disord. (2010) 11:140. doi: 10.1186/1471-2474-11-140

PubMed Abstract | Crossref Full Text | Google Scholar

53. Kitagawa M, Sugimoto T, Ogawa I, Miyauchi M, Hirata S, and Sugiyama E. Importance of anti-centromere antibodies in the diagnosis of sjögren's syndrome. J Oral Sci. (2022) 64:324–6. doi: 10.2334/josnusd.22-0231

PubMed Abstract | Crossref Full Text | Google Scholar

54. Lee KE, Kang JH, Lee JW, Wen L, Park DJ, Kim TJ, et al. Anti-centromere antibody-positive sjögren's syndrome: A distinct clinical subgroup? Int J rheumatic Dis. (2015) 18:776–82. doi: 10.1111/1756-185x.12684

PubMed Abstract | Crossref Full Text | Google Scholar

55. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatol (Baltimore Md). (2007) 45:118–27. doi: 10.1002/hep.21472

PubMed Abstract | Crossref Full Text | Google Scholar

56. Ding D, Jia G, Cui L, Liu Y, Wang X, Sun R, et al. The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: enhancing the prognostic utility on the globe scoring system. Digestive liver disease: Off J Ital Soc Gastroenterol Ital Assoc Study Liver. (2025) 57:861–8. doi: 10.1016/j.dld.2024.12.024

PubMed Abstract | Crossref Full Text | Google Scholar

57. Zabotti A, Giovannini I, Longhino S, Manfrè V, Rizzo MT, De Vita S, et al. Nuts and bolts of salivary gland pathology in primary sjögren's syndrome. Clin Exp Rheumatol. (2023) 41:2525–37. doi: 10.55563/clinexprheumatol/fcjoqx

PubMed Abstract | Crossref Full Text | Google Scholar

58. Qi W, Tian J, Wang G, Yan Y, Wang T, Wei Y, et al. Advances in cellular and molecular pathways of salivary gland damage in sjögren's syndrome. Front Immunol. (2024) 15:1405126. doi: 10.3389/fimmu.2024.1405126

PubMed Abstract | Crossref Full Text | Google Scholar

59. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of Malignant lymphoma in primary sjögren's syndrome. Ann rheumatic Dis. (2011) 70:1363–8. doi: 10.1136/ard.2010.144782

PubMed Abstract | Crossref Full Text | Google Scholar

60. Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, et al. The british society of gastroenterology/uk-pbc primary biliary cholangitis treatment and management guidelines. Gut. (2018) 67:1568–94. doi: 10.1136/gutjnl-2017-315259

PubMed Abstract | Crossref Full Text | Google Scholar

61. Tan D and Goodman ZD. Liver biopsy in primary biliary cholangitis: indications and interpretation. Clinics liver Dis. (2018) 22:579–88. doi: 10.1016/j.cld.2018.03.008

PubMed Abstract | Crossref Full Text | Google Scholar

62. Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. (2021) 113:170–84. doi: 10.32074/1591-951x-245

PubMed Abstract | Crossref Full Text | Google Scholar

63. Ryo K, Yamada H, Nakagawa Y, Tai Y, Obara K, Inoue H, et al. Possible involvement of oxidative stress in salivary gland of patients with sjogren's syndrome. Pathobiology: J immunopathology Mol Cell Biol. (2006) 73:252–60. doi: 10.1159/000098211

PubMed Abstract | Crossref Full Text | Google Scholar

64. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(Reg) balance by hypoxia-inducible factor 1. Cell. (2011) 146:772–84. doi: 10.1016/j.cell.2011.07.033

PubMed Abstract | Crossref Full Text | Google Scholar

65. Pringle S, Wang X, Verstappen G, Terpstra JH, Zhang CK, He A, et al. Salivary gland stem cells age prematurely in primary sjögren's syndrome. Arthritis Rheumatol (Hoboken NJ). (2019) 71:133–42. doi: 10.1002/art.40659

PubMed Abstract | Crossref Full Text | Google Scholar

66. ColaFrancesco S, Vomero M, Iannizzotto V, Minniti A, Barbati C, Arienzo F, et al. Autophagy occurs in lymphocytes infiltrating sjögren's syndrome minor salivary glands and correlates with histological severity of salivary gland lesions. Arthritis Res Ther. (2020) 22:238. doi: 10.1186/s13075-020-02317-6

PubMed Abstract | Crossref Full Text | Google Scholar

67. Voynova E, Lefebvre F, Qadri A, and Muller S. Correction of autophagy impairment inhibits pathology in the nod.H-2h4 mouse model of primary sjögren's syndrome. J Autoimmun. (2020) 108:102418. doi: 10.1016/j.jaut.2020.102418

PubMed Abstract | Crossref Full Text | Google Scholar

68. Sasaki M, Sato Y, and Nakanuma Y. A heterogeneous subtype of biliary epithelial senescence may be involved in the pathogenesis of primary biliary cholangitis. Clinics Res Hepatol Gastroenterol. (2025) 49:102512. doi: 10.1016/j.clinre.2024.102512

PubMed Abstract | Crossref Full Text | Google Scholar

69. Sasaki M, Miyakoshi M, Sato Y, and Nakanuma Y. Autophagy mediates the process of cellular senescence characterizing bile duct damages in primary biliary cirrhosis. Lab investigation; J Tech Methods Pathol. (2010) 90:835–43. doi: 10.1038/labinvest.2010.56

PubMed Abstract | Crossref Full Text | Google Scholar

70. Sasaki M, Sato Y, and Nakanuma Y. Increased P16(Ink4a)-expressing senescent bile ductular cells are associated with inadequate response to ursodeoxycholic acid in primary biliary cholangitis. J Autoimmun. (2020) 107:102377. doi: 10.1016/j.jaut.2019.102377

PubMed Abstract | Crossref Full Text | Google Scholar

71. Xiang N, Xu H, Zhou Z, Wang J, Cai P, Wang L, et al. Single-cell transcriptome profiling reveals immune and stromal cell heterogeneity in primary sjögren's syndrome. iScience. (2023) 26:107943. doi: 10.1016/j.isci.2023.107943

PubMed Abstract | Crossref Full Text | Google Scholar

72. Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Mourcin F, et al. Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proc Natl Acad Sci United States America. (2019) 116:13490–7. doi: 10.1073/pnas.1905301116

PubMed Abstract | Crossref Full Text | Google Scholar

73. Nayar S, Turner JD, Asam S, Fennell E, Pugh M, ColaFrancesco S, et al. Molecular and spatial analysis of tertiary lymphoid structures in sjogren's syndrome. Nat Commun. (2025) 16:5. doi: 10.1038/s41467-024-54686-0

PubMed Abstract | Crossref Full Text | Google Scholar

74. Yang L, Maruo S, and Takada K. Cd21-mediated entry and stable infection by epstein-barr virus in canine and rat cells. J Virol. (2000) 74:10745–51. doi: 10.1128/jvi.74.22.10745-10751.2000

PubMed Abstract | Crossref Full Text | Google Scholar

75. Yang AT, Kim YO, Yan XZ, Abe H, Aslam M, Park KS, et al. Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis. Cell Mol Gastroenterol Hepatol. (2023) 15:841–67. doi: 10.1016/j.jcmgh.2022.12.005

PubMed Abstract | Crossref Full Text | Google Scholar

76. Wunsch E, Milkiewicz M, Wasik U, Trottier J, Kempińska-Podhorodecka A, Elias E, et al. Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci Rep. (2015) 5:13462. doi: 10.1038/srep13462

PubMed Abstract | Crossref Full Text | Google Scholar

77. Chuang YH, Lian ZX, Tsuneyama K, Chiang BL, Ansari AA, Coppel RL, et al. Increased killing activity and decreased cytokine production in nk cells in patients with primary biliary cirrhosis. J Autoimmun. (2006) 26:232–40. doi: 10.1016/j.jaut.2006.04.001

PubMed Abstract | Crossref Full Text | Google Scholar

78. Sánchez-Cerrillo I, Calzada-Fraile D, Triguero-Martínez A, Calvet-Mirabent M, Popova O, Delgado-Arévalo C, et al. Mica/B-dependent activation of natural killer cells by cd64(+) inflammatory type 2 dendritic cells contributes to autoimmunity. EMBO J. (2023) 42:e113714. doi: 10.15252/embj.2023113714

PubMed Abstract | Crossref Full Text | Google Scholar

79. Schuster IS, Sng XYX, Lau CM, Powell DR, Weizman OE, Fleming P, et al. Infection induces tissue-resident memory nk cells that safeguard tissue health. Immunity. (2023) 56:531–46.e6. doi: 10.1016/j.immuni.2023.01.016

PubMed Abstract | Crossref Full Text | Google Scholar

80. Ushio A, Arakaki R, Otsuka K, Yamada A, Tsunematsu T, Kudo Y, et al. Ccl22-producing resident macrophages enhance T cell response in sjögren's syndrome. Front Immunol. (2018) 9:2594. doi: 10.3389/fimmu.2018.02594

PubMed Abstract | Crossref Full Text | Google Scholar

81. Zong Y, Yang Y, Zhao J, Li L, Luo D, Hu J, et al. Characterisation of macrophage infiltration and polarisation based on integrated transcriptomic and histological analyses in primary sjögren's syndrome. Front Immunol. (2023) 14:1292146. doi: 10.3389/fimmu.2023.1292146

PubMed Abstract | Crossref Full Text | Google Scholar

82. Ma D, Liu X, Li J, Wu H, Ma J, and Tai W. Elmo1 regulates macrophage directed migration and attenuates inflammation via nf-Kb signaling pathway in primary biliary cholangitis. Digestive liver disease: Off J Ital Soc Gastroenterol Ital Assoc Study Liver. (2024) 56:1897–905. doi: 10.1016/j.dld.2024.05.012

PubMed Abstract | Crossref Full Text | Google Scholar

83. Maehara T, Moriyama M, Hayashida JN, Tanaka A, Shinozaki S, Kubo Y, et al. Selective localization of T helper subsets in labial salivary glands from primary sjögren's syndrome patients. Clin Exp Immunol. (2012) 169:89–99. doi: 10.1111/j.1365-2249.2012.04606.x

PubMed Abstract | Crossref Full Text | Google Scholar

84. Harada K, Tsuneyama K, Yasoshima M, Kanemori Y, Ohta H, Masuda S, et al. Type1 and type2 memory T cells imbalance shown by expression of intrahepatic chemokine receptors relates to pathogenesis of primary biliary cirrhosis. Hepatol research: Off J Japan Soc Hepatol. (2002) 24:290. doi: 10.1016/s1386-6346(02)00091-8

PubMed Abstract | Crossref Full Text | Google Scholar

85. Harada K and Nakanuma Y. Molecular mechanisms of cholangiopathy in primary biliary cirrhosis. Med Mol morphology. (2006) 39:55–61. doi: 10.1007/s00795-006-0321-z

PubMed Abstract | Crossref Full Text | Google Scholar

86. Luo D, Chen Y, Zhou N, Li T, and Wang H. Blockade of th17 response by il-38 in primary sjögren's syndrome. Mol Immunol. (2020) 127:107–11. doi: 10.1016/j.molimm.2020.09.006

PubMed Abstract | Crossref Full Text | Google Scholar

87. Jin X, Bai Y, Xu X, Wu F, Long X, and Yao Y. Usp18-mediated protein stabilization of notch1 is associated with altered th17/treg cell ratios and B cell-mediated autoantibody secretion in sjögren syndrome. Immunologic Res. (2024) 73:10. doi: 10.1007/s12026-024-09566-6

PubMed Abstract | Crossref Full Text | Google Scholar

88. Yang CY, Ma X, Tsuneyama K, Huang S, Takahashi T, Chalasani NP, et al. Il-12/th1 and il-23/th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatol (Baltimore Md). (2014) 59:1944–53. doi: 10.1002/hep.26979

PubMed Abstract | Crossref Full Text | Google Scholar

89. Shi T, Zhang T, Zhang L, Yang Y, Zhang H, and Zhang F. The distribution and the fibrotic role of elevated inflammatory th17 cells in patients with primary biliary cirrhosis. Medicine. (2015) 94:e1888. doi: 10.1097/md.0000000000001888

PubMed Abstract | Crossref Full Text | Google Scholar

90. Tanaka Y, Sotome T, Inoue A, Mukozu T, Kuwabara T, Mikami T, et al. Satb1 conditional knockout results in sjögren's syndrome in mice. J Immunol (Baltimore Md: 1950). (2017) 199:4016–22. doi: 10.4049/jimmunol.1700550

PubMed Abstract | Crossref Full Text | Google Scholar

91. Chen YY, Jeffery HC, Hunter S, Bhogal R, Birtwistle J, Braitch MK, et al. Human intrahepatic regulatory T cells are functional, require il-2 from effector cells for survival, and are susceptible to fas ligand-mediated apoptosis. Hepatol (Baltimore Md). (2016) 64:138–50. doi: 10.1002/hep.28517

PubMed Abstract | Crossref Full Text | Google Scholar

92. Hao LR, Li XF, Gao C, Cao L, Han ZY, and Gao H. Th17/treg cell level and clinical characteristics of peripheral blood of patients with sjogren's syndrome complicated with primary biliary cirrhosis. Medicine. (2019) 98:e15952. doi: 10.1097/md.0000000000015952

PubMed Abstract | Crossref Full Text | Google Scholar

93. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, and Rudensky AY. Role of conserved non-coding DNA elements in the foxp3 gene in regulatory T-cell fate. Nature. (2010) 463:808–12. doi: 10.1038/nature08750

PubMed Abstract | Crossref Full Text | Google Scholar

94. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, and Moutsopoulos HM. Foxp3+ T-regulatory cells in sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol. (2008) 173:1389–96. doi: 10.2353/ajpath.2008.080246

PubMed Abstract | Crossref Full Text | Google Scholar

95. Jiang T, Zhang HW, Wen YP, Yin YS, Yang LH, Yang J, et al. 5-aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the foxp3 methylation and promoting the treg/th17 balance. Int Immunopharmacol. (2021) 96:107820. doi: 10.1016/j.intimp.2021.107820

PubMed Abstract | Crossref Full Text | Google Scholar

96. Zhang W, Sharma R, Ju ST, He XS, Tao Y, Tsuneyama K, et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatol (Baltimore Md). (2009) 49:545–52. doi: 10.1002/hep.22651

PubMed Abstract | Crossref Full Text | Google Scholar

97. Pontarini E, Murray-Brown WJ, Croia C, Lucchesi D, Conway J, Rivellese F, et al. Unique expansion of il-21+ Tfh and tph cells under control of icos identifies sjögren's syndrome with ectopic germinal centres and malt lymphoma. Ann rheumatic Dis. (2020) 79:1588–99. doi: 10.1136/annrheumdis-2020-217646

PubMed Abstract | Crossref Full Text | Google Scholar

98. Zheng J, Wang T, Zhang L, and Cui L. Dysregulation of circulating tfr/tfh ratio in primary biliary cholangitis. Scandinavian J Immunol. (2017) 86:452–61. doi: 10.1111/sji.12616

PubMed Abstract | Crossref Full Text | Google Scholar

99. Szabó K, Jámbor I, Szántó A, Horváth IF, Tarr T, Nakken B, et al. The imbalance of circulating follicular T helper cell subsets in primary sjögren's syndrome associates with serological alterations and abnormal B-cell distribution. Front Immunol. (2021) 12:639975. doi: 10.3389/fimmu.2021.639975

PubMed Abstract | Crossref Full Text | Google Scholar

100. Huang J, Tang J, Zhang C, Liu T, Deng Z, and Liu L. Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary sjögren's syndrome. J Trans Autoimmun. (2024) 9:100248. doi: 10.1016/j.jtauto.2024.100248

PubMed Abstract | Crossref Full Text | Google Scholar

101. Zhao SX, Li WC, Fu N, Zhou GD, Liu SH, Jiang LN, et al. Emperipolesis mediated by cd8(+) T cells correlates with biliary epithelia cell injury in primary biliary cholangitis. J Cell Mol Med. (2020) 24:1268–75. doi: 10.1111/jcmm.14752

PubMed Abstract | Crossref Full Text | Google Scholar

102. Shi H, Xu X, Wang S, Chen Q, Zhang F, Guo H, et al. The relationship between cxcr6+Cd8+T cells and clinicopathological parameters in patients with primary biliary cholangitis. Hepatol Int. (2024) 18:1555–65. doi: 10.1007/s12072-024-10715-0

PubMed Abstract | Crossref Full Text | Google Scholar

103. Gao CY, Yao Y, Li L, Yang SH, Chu H, Tsuneyama K, et al. Tissue-resident memory cd8+ T cells acting as mediators of salivary gland damage in a murine model of sjögren's syndrome. Arthritis Rheumatol (Hoboken NJ). (2019) 71:121–32. doi: 10.1002/art.40676

PubMed Abstract | Crossref Full Text | Google Scholar

104. Yang XX, Yang C, Wang L, Zhou YB, Yuan X, Xiang N, et al. Molecular mechanism of sphingosine-1-phosphate receptor 1 regulating cd4(+) tissue memory in situ T cells in primary sjogren's syndrome. Int J Gen Med. (2021) 14:6177–88. doi: 10.2147/ijgm.S327304

PubMed Abstract | Crossref Full Text | Google Scholar

105. Davies SP, Ronca V, Wootton GE, Krajewska NM, Bozward AG, Fiancette R, et al. Expression of E-cadherin by cd8(+) T cells promotes their invasion into biliary epithelial cells. Nat Commun. (2024) 15:853. doi: 10.1038/s41467-024-44910-2

PubMed Abstract | Crossref Full Text | Google Scholar

106. Du W, Han M, Zhu X, Xiao F, Huang E, Che N, et al. The multiple roles of B cells in the pathogenesis of sjögren's syndrome. Front Immunol. (2021) 12:684999. doi: 10.3389/fimmu.2021.684999

PubMed Abstract | Crossref Full Text | Google Scholar

107. Sakkas LI. Regulatory B cells in autoimmune rheumatic diseases. Mediterr J Rheumatol. (2017) 28:75–9. doi: 10.31138/mjr.28.2.75

PubMed Abstract | Crossref Full Text | Google Scholar

108. Lin W, Jin L, Chen H, Wu Q, Fei Y, Zheng W, et al. B cell subsets and dysfunction of regulatory B cells in igg4-related diseases and primary sjögren's syndrome: the similarities and differences. Arthritis Res Ther. (2014) 16:R118. doi: 10.1186/ar4571

PubMed Abstract | Crossref Full Text | Google Scholar

109. Chen Q, Lai L, Chi X, Lu X, Wu H, Sun J, et al. Cd19(+)Cd24(Hi)Cd38(Hi) B cell dysfunction in primary biliary cholangitis. Mediators Inflammation. (2020) 2020:3019378. doi: 10.1155/2020/3019378

PubMed Abstract | Crossref Full Text | Google Scholar

110. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with sjögren's syndrome. Arthritis rheumatism. (2002) 46:2160–71. doi: 10.1002/art.10445

PubMed Abstract | Crossref Full Text | Google Scholar

111. Hansen A, Reiter K, Ziprian T, Jacobi A, Hoffmann A, Gosemann M, et al. Dysregulation of chemokine receptor expression and function by B cells of patients with primary sjögren's syndrome. Arthritis rheumatism. (2005) 52:2109–19. doi: 10.1002/art.21129

PubMed Abstract | Crossref Full Text | Google Scholar

112. Hansen A, Lipsky PE, and Dörner T. B cells in sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther. (2007) 9:218. doi: 10.1186/ar2210

PubMed Abstract | Crossref Full Text | Google Scholar

113. Wang L, Sun X, Qiu J, Cai Y, Ma L, Zhao P, et al. Increased numbers of circulating icos⁺ Follicular helper T and cd38⁺ Plasma cells in patients with newly diagnosed primary biliary cirrhosis. Digestive Dis Sci. (2015) 60:405–13. doi: 10.1007/s10620-014-3372-3

PubMed Abstract | Crossref Full Text | Google Scholar

114. Rivière E, Pascaud J, Tchitchek N, Boudaoud S, Paoletti A, Ly B, et al. Salivary gland epithelial cells from patients with sjögren's syndrome induce B-lymphocyte survival and activation. Ann rheumatic Dis. (2020) 79:1468–77. doi: 10.1136/annrheumdis-2019-216588

PubMed Abstract | Crossref Full Text | Google Scholar

115. Szyszko EA, Brokstad KA, Oijordsbakken G, Jonsson MV, Jonsson R, and Skarstein K. Salivary glands of primary sjögren's syndrome patients express factors vital for plasma cell survival. Arthritis Res Ther. (2011) 13:R2. doi: 10.1186/ar3220

PubMed Abstract | Crossref Full Text | Google Scholar

116. Cannons JL, Lu KT, and Schwartzberg PL. T follicular helper cell diversity and plasticity. Trends Immunol. (2013) 34:200–7. doi: 10.1016/j.it.2013.01.001

PubMed Abstract | Crossref Full Text | Google Scholar

117. Li Y, Wang W, Tang L, He X, Yan X, Zhang X, et al. Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ Lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis. Hepatol (Baltimore Md). (2015) 61:1998–2007. doi: 10.1002/hep.27725

PubMed Abstract | Crossref Full Text | Google Scholar

118. Zhang J, Zhang W, Leung PS, Bowlus CL, Dhaliwal S, Coppel RL, et al. Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatol (Baltimore Md). (2014) 60:1708–16. doi: 10.1002/hep.27313

PubMed Abstract | Crossref Full Text | Google Scholar

119. Gao X, Xiao G, Yang F, Dou R, Xue M, Zhang Y, et al. Laboratory risk factors for coexistent primary biliary cholangitis in patients with sjögren's syndrome: A retrospective study. BMC Gastroenterol. (2023) 23:220. doi: 10.1186/s12876-023-02859-4

PubMed Abstract | Crossref Full Text | Google Scholar

120. Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, et al. Antibodies to ss-a/ro-52kd and centromere in autoimmune liver disease: A clue to diagnosis and prognosis of primary biliary cirrhosis. Alimentary Pharmacol Ther. (2007) 26:831–8. doi: 10.1111/j.1365-2036.2007.03433.x

PubMed Abstract | Crossref Full Text | Google Scholar

121. Vinuesa CG, Sanz I, and Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol. (2009) 9:845–57. doi: 10.1038/nri2637

PubMed Abstract | Crossref Full Text | Google Scholar

122. Traianos EY, Locke J, Lendrem D, Bowman S, Hargreaves B, Macrae V, et al. Serum cxcl13 levels are associated with lymphoma risk and lymphoma occurrence in primary sjögren's syndrome. Rheumatol Int. (2020) 40:541–8. doi: 10.1007/s00296-020-04524-5

PubMed Abstract | Crossref Full Text | Google Scholar

123. Ittah M, Miceli-Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N, et al. B cell-activating factor of the tumor necrosis factor family (Baff) is expressed under stimulation by interferon in salivary gland epithelial cells in primary sjögren's syndrome. Arthritis Res Ther. (2006) 8:R51. doi: 10.1186/ar1912

PubMed Abstract | Crossref Full Text | Google Scholar

124. Corsiero E, Nerviani A, Bombardieri M, and Pitzalis C. Ectopic lymphoid structures: powerhouse of autoimmunity. Front Immunol. (2016) 7:430. doi: 10.3389/fimmu.2016.00430

PubMed Abstract | Crossref Full Text | Google Scholar

125. Mackay F, Groom JR, and Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of sjögren's syndrome. Curr Opin Rheumatol. (2007) 19:406–13. doi: 10.1097/BOR.0b013e328277ef4c

PubMed Abstract | Crossref Full Text | Google Scholar

126. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmström P, Wahren-Herlenius M, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with sjögren's syndrome. Arthritis rheumatism. (2003) 48:3187–201. doi: 10.1002/art.11311

PubMed Abstract | Crossref Full Text | Google Scholar

127. Jonsson MV, Skarstein K, Jonsson R, and Brun JG. Serological implications of germinal center-like structures in primary sjögren's syndrome. J Rheumatol. (2007) 34:2044–9.

PubMed Abstract | Google Scholar

128. Guggino G, Rizzo C, Mohammadnezhad L, Lo Pizzo M, Lentini VL, Di Liberto D, et al. Possible role for il-40 and il-40-producing cells in the lymphocytic infiltrated salivary glands of patients with primary sjögren's syndrome. RMD Open. (2023) 9. doi: 10.1136/rmdopen-2022-002738

PubMed Abstract | Crossref Full Text | Google Scholar

129. Ciecko AE, Foda B, Barr JY, Ramanathan S, Atkinson MA, Serreze DV, et al. Interleukin-27 is essential for type 1 diabetes development and sjögren syndrome-like inflammation. Cell Rep. (2019) 29:3073–86.e5. doi: 10.1016/j.celrep.2019.11.010

PubMed Abstract | Crossref Full Text | Google Scholar

130. Liang Y, Zhang Z, Li J, Luo W, Jiang T, and Yang Z. Association between il-7 and primary sjögren's syndrome: A single-center study and a systematic scoping review. Int Immunopharmacol. (2022) 108:108758. doi: 10.1016/j.intimp.2022.108758

PubMed Abstract | Crossref Full Text | Google Scholar

131. Soyfoo MS and Nicaise C. Pathophysiologic role of interleukin-33/st2 in sjögren's syndrome. Autoimmun Rev. (2021) 20:102756. doi: 10.1016/j.autrev.2021.102756

PubMed Abstract | Crossref Full Text | Google Scholar

132. Wang Q, Wang Y, Qiao W, Xu B, Liu Y, Zhang X, et al. The effect of serum il-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism. Front Immunol. (2022) 13:995223. doi: 10.3389/fimmu.2022.995223

PubMed Abstract | Crossref Full Text | Google Scholar

133. Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, Moritoki Y, et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type ii mice. Hepatol (Baltimore Md). (2009) 50:1494–500. doi: 10.1002/hep.23132

PubMed Abstract | Crossref Full Text | Google Scholar

134. Lin CI, Wang YW, Su KY, and Chuang YH. Interleukin-37 exacerbates liver inflammation and promotes ifn-Γ Production in nk cells. Int Immunopharmacol. (2024) 142:113086. doi: 10.1016/j.intimp.2024.113086

PubMed Abstract | Crossref Full Text | Google Scholar

135. Yang J, Su J, Chai K, and Liu H. The role of th9 cd4(+) T cells and il-9 during primary sjogren's syndrome. J Clin Lab Anal. (2022) 36:e24646. doi: 10.1002/jcla.24646

PubMed Abstract | Crossref Full Text | Google Scholar

136. Fujimura T, Fujimoto T, Itaya-Hironaka A, Miyaoka T, Yoshimoto K, Sakuramoto-Tsuchida S, et al. Significance of interleukin-6/stat pathway for the gene expression of reg Iα, a new autoantigen in sjögren's syndrome patients, in salivary duct epithelial cells. Clin Rev Allergy Immunol. (2017) 52:351–63. doi: 10.1007/s12016-016-8570-7

PubMed Abstract | Crossref Full Text | Google Scholar

137. Liu S, Zhang Q, Zhang M, Zhong X, Wang W, Wang L, et al. Reduced circulating interleukin 35 is associated with enhanced peripheral T cell function in primary biliary cholangitis. Biomolecules biomedicine. (2023) 23:248–58. doi: 10.17305/bjbms.2022.8147

PubMed Abstract | Crossref Full Text | Google Scholar

138. Fusconi M, Musy I, Valente D, Maggi E, Priori R, Pecorella I, et al. Immunohistochemical detection of il-17 and il-23 improves the identification of patients with a possible diagnosis of sjogren's syndrome. Pathology Res Pract. (2020) 216:153137. doi: 10.1016/j.prp.2020.153137

PubMed Abstract | Crossref Full Text | Google Scholar

139. Sun Q, Wang Q, Feng N, Meng Y, Li B, Luo D, et al. The expression and clinical significance of serum il-17 in patients with primary biliary cirrhosis. Ann Trans Med. (2019) 7:389. doi: 10.21037/atm.2019.07.100

PubMed Abstract | Crossref Full Text | Google Scholar

140. Qian C, Jiang T, Zhang W, Ren C, Wang Q, Qin Q, et al. Increased il-23 and il-17 expression by peripheral blood cells of patients with primary biliary cirrhosis. Cytokine. (2013) 64:172–80. doi: 10.1016/j.cyto.2013.07.005

PubMed Abstract | Crossref Full Text | Google Scholar

141. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, and Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer research: an Off J Am Assoc Cancer Res. (2011) 17:2619–27. doi: 10.1158/1078-0432.Ccr-10-1114

PubMed Abstract | Crossref Full Text | Google Scholar

142. Shao T, Leung PSC, Zhang W, Tsuneyama K, Ridgway WM, Young HA, et al. Treatment with a jak1/2 inhibitor ameliorates murine autoimmune cholangitis induced by ifn overexpression. Cell Mol Immunol. (2022) 19:1130–40. doi: 10.1038/s41423-022-00904-y

PubMed Abstract | Crossref Full Text | Google Scholar

143. Peng Y, Wu X, Zhang S, Deng C, Zhao L, Wang M, et al. The potential roles of type I interferon activated neutrophils and neutrophil extracellular traps (Nets) in the pathogenesis of primary sjögren's syndrome. Arthritis Res Ther. (2022) 24:170. doi: 10.1186/s13075-022-02860-4

PubMed Abstract | Crossref Full Text | Google Scholar

144. Cao T, Zhou J, Liu Q, Mao T, Chen B, Wu Q, et al. Interferon-Γ Induces salivary gland epithelial cell ferroptosis in sjogren's syndrome via jak/stat1-mediated inhibition of system xc(). Free Radical Biol Med. (2023) 205:116–28. doi: 10.1016/j.freeradbiomed.2023.05.027

PubMed Abstract | Crossref Full Text | Google Scholar

145. Takii Y, Nakamura M, Ito M, Yokoyama T, Komori A, Shimizu-Yoshida Y, et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab investigation; J Tech Methods Pathol. (2005) 85:908–20. doi: 10.1038/labinvest.3700285

PubMed Abstract | Crossref Full Text | Google Scholar

146. Rubtsova K, Marrack P, and Rubtsov AV. Tlr7, ifnγ, and T-bet: their roles in the development of abcs in female-biased autoimmunity. Cell Immunol. (2015) 294:80–3. doi: 10.1016/j.cellimm.2014.12.002

PubMed Abstract | Crossref Full Text | Google Scholar

147. Imgenberg-Kreuz J, Sandling JK, Norheim KB, Johnsen SJA, Omdal R, Syvänen AC, et al. DNA methylation-based interferon scores associate with sub-phenotypes in primary sjögren's syndrome. Front Immunol. (2021) 12:702037. doi: 10.3389/fimmu.2021.702037

PubMed Abstract | Crossref Full Text | Google Scholar

148. Guldner HH, Szostecki C, Grötzinger T, and Will H. Ifn enhance expression of sp100, an autoantigen in primary biliary cirrhosis. J Immunol (Baltimore Md: 1950). (1992) 149:4067–73. doi: 10.4049/jimmunol.149.12.4067

PubMed Abstract | Crossref Full Text | Google Scholar

149. Xu YF, Yao Y, Ma M, Yang SH, Jiang P, Wang J, et al. The proinflammatory cytokines il-18, il-21, and ifn-Γ Differentially regulate liver inflammation and anti-mitochondrial antibody level in a murine model of primary biliary cholangitis. J Immunol Res. (2022) 2022:7111445. doi: 10.1155/2022/7111445

PubMed Abstract | Crossref Full Text | Google Scholar

150. Chen C, Liang Y, Zhang Z, Zhang Z, and Yang Z. Relationships between increased circulating ykl-40, il-6 and tnf-A Levels and phenotypes and disease activity of primary sjögren's syndrome. Int Immunopharmacol. (2020) 88:106878. doi: 10.1016/j.intimp.2020.106878

PubMed Abstract | Crossref Full Text | Google Scholar

151. Hanada S, Harada M, Koga H, Kawaguchi T, Taniguchi E, Kumashiro R, et al. Tumor necrosis factor-alpha and interferon-gamma directly impair epithelial barrier function in cultured mouse cholangiocytes. Liver international: Off J Int Assoc Study Liver. (2003) 23:3–11. doi: 10.1034/j.1600-0676.2003.01707.x

PubMed Abstract | Crossref Full Text | Google Scholar

152. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, and Skarstein K. Association between circulating levels of the novel tnf family members april and baff and lymphoid organization in primary sjögren's syndrome. J Clin Immunol. (2005) 25:189–201. doi: 10.1007/s10875-005-4091-5

PubMed Abstract | Crossref Full Text | Google Scholar

153. Carrillo-Ballesteros FJ, Palafox-Sánchez CA, Franco-Topete RA, Muñoz-Valle JF, Orozco-Barocio G, Martínez-Bonilla GE, et al. Expression of baff and baff receptors in primary sjögren's syndrome patients with ectopic germinal center-like structures. Clin Exp Med. (2020) 20:615–26. doi: 10.1007/s10238-020-00637-0

PubMed Abstract | Crossref Full Text | Google Scholar

154. Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, and Mariette X. Expression of baff (Blys) in T cells infiltrating labial salivary glands from patients with sjögren's syndrome. J Pathol. (2004) 202:496–502. doi: 10.1002/path.1533

PubMed Abstract | Crossref Full Text | Google Scholar

155. Thapa M, Tedesco D, Gumber S, Elrod EJ, Han JH, Kitchens WH, et al. Blockade of baff reshapes the hepatic B cell receptor repertoire and attenuates autoantibody production in cholestatic liver disease. J Immunol (Baltimore Md: 1950). (2020) 204:3117–28. doi: 10.4049/jimmunol.1900391

PubMed Abstract | Crossref Full Text | Google Scholar

156. Zhang B, Hu M, Zhang P, Cao H, Wang Y, Wang Z, et al. Baff promotes regulatory T-cell apoptosis and blocks cytokine production by activating B cells in primary biliary cirrhosis. Braz J Med Biol Res = Rev Bras pesquisas medicas e biologicas. (2013) 46:433–9. doi: 10.1590/1414-431x20132665

PubMed Abstract | Crossref Full Text | Google Scholar

157. Migita K, Ilyassova B, Kovzel EF, Nersesov A, Abiru S, Maeda Y, et al. Serum baff and april levels in patients with pbc. Clin Immunol (Orlando Fla). (2010) 134:217–25. doi: 10.1016/j.clim.2009.09.007

PubMed Abstract | Crossref Full Text | Google Scholar

158. Nocturne G, Seror R, Fogel O, Belkhir R, Boudaoud S, Saraux A, et al. Cxcl13 and ccl11 serum levels and lymphoma and disease activity in primary sjögren's syndrome. Arthritis Rheumatol (Hoboken NJ). (2015) 67:3226–33. doi: 10.1002/art.39315

PubMed Abstract | Crossref Full Text | Google Scholar

159. He J, Xu C, Zhu Y, Xu M, Chen Y, Guo L, et al. Clinical significance of the expression levels of serum transforming growth factor-B and cxc type chemokine ligand 13 in primary sjogren's syndrome patients. Clin Rheumatol. (2023) 42:3283–8. doi: 10.1007/s10067-023-06783-6

PubMed Abstract | Crossref Full Text | Google Scholar

160. Blokland SLM, Kislat A, Homey B, Smithson GM, Kruize AA, Radstake T, et al. Decreased circulating cxcr3 + ccr9+T helper cells are associated with elevated levels of their ligands cxcl10 and ccl25 in the salivary gland of patients with sjögren's syndrome to facilitate their concerted migration. Scandinavian J Immunol. (2020) 91:e12852. doi: 10.1111/sji.12852

PubMed Abstract | Crossref Full Text | Google Scholar

161. Liu Z, Li F, Pan A, Xue H, Jiang S, Zhu C, et al. Elevated ccl19/ccr7 expression during the disease process of primary sjögren's syndrome. Front Immunol. (2019) 10:795. doi: 10.3389/fimmu.2019.00795

PubMed Abstract | Crossref Full Text | Google Scholar

162. Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, Walker LS, et al. Epithelial inflammation is associated with ccl28 production and the recruitment of regulatory T cells expressing ccr10. J Immunol (Baltimore Md: 1950). (2006) 177:593–603. doi: 10.4049/jimmunol.177.1.593

PubMed Abstract | Crossref Full Text | Google Scholar

163. Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, et al. Human liver-resident cd56(Bright)/cd16(Neg) nk cells are retained within hepatic sinusoids via the engagement of ccr5 and cxcr6 pathways. J Autoimmun. (2016) 66:40–50. doi: 10.1016/j.jaut.2015.08.011

PubMed Abstract | Crossref Full Text | Google Scholar

164. Chen S, Lv T, Sun G, Li S, Duan W, Zhang C, et al. Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis. Hepatol Int. (2022) 16:195–206. doi: 10.1007/s12072-021-10267-7

PubMed Abstract | Crossref Full Text | Google Scholar

165. Lin F, Shi H, Liu D, Zhang Z, Luo W, Mao P, et al. Association of ccl11, ccl24 and ccl26 with primary biliary cholangitis. Int Immunopharmacol. (2019) 67:372–7. doi: 10.1016/j.intimp.2018.12.026

PubMed Abstract | Crossref Full Text | Google Scholar

166. Astorri E, Scrivo R, Bombardieri M, Picarelli G, Pecorella I, Porzia A, et al. Cx3cl1 and cx3cr1 expression in tertiary lymphoid structures in salivary gland infiltrates: fractalkine contribution to lymphoid neogenesis in sjogren's syndrome. Rheumatol (Oxford England). (2014) 53:611–20. doi: 10.1093/rheumatology/ket401

PubMed Abstract | Crossref Full Text | Google Scholar

167. Sasaki M, Miyakoshi M, Sato Y, and Nakanuma Y. Chemokine-chemokine receptor ccl2-ccr2 and cx3cl1-cx3cr1 axis may play a role in the aggravated inflammation in primary biliary cirrhosis. Digestive Dis Sci. (2014) 59:358–64. doi: 10.1007/s10620-013-2920-6

PubMed Abstract | Crossref Full Text | Google Scholar

168. Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, et al. Cxcl13, ccl21, and cxcl12 expression in salivary glands of patients with sjogren's syndrome and malt lymphoma: association with reactive and Malignant areas of lymphoid organization. J Immunol (Baltimore Md: 1950). (2008) 180:5130–40. doi: 10.4049/jimmunol.180.7.5130

PubMed Abstract | Crossref Full Text | Google Scholar

169. Zhang L, Zhao C, Dai W, Tong H, Yang W, Huang Z, et al. Disruption of cholangiocyte-B cell crosstalk by blocking the cxcl12-cxcr4 axis alleviates liver fibrosis. Cell Mol Life sciences: CMLS. (2023) 80:379. doi: 10.1007/s00018-023-05032-y

PubMed Abstract | Crossref Full Text | Google Scholar

170. Kim JW, Ahn MH, Jung JY, Suh CH, Han JH, and Kim HA. Role of chemokines cxcl9, cxcl10, cxcl11, and cxcr3 in the serum and minor salivary gland tissues of patients with sjögren's syndrome. Clin Exp Med. (2024) 24:133. doi: 10.1007/s10238-024-01401-4

PubMed Abstract | Crossref Full Text | Google Scholar

171. Chuang YH, Lian ZX, Cheng CM, Lan RY, Yang GX, Moritoki Y, et al. Increased levels of chemokine receptor cxcr3 and chemokines ip-10 and mig in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun. (2005) 25:126–32. doi: 10.1016/j.jaut.2005.08.009

PubMed Abstract | Crossref Full Text | Google Scholar

172. Lee KE, Kang JH, Yim YR, Kim JE, Lee JW, Wen L, et al. Predictive significance of ccl21 and cxcl13 levels in the minor salivary glands of patients with sjögren's syndrome. Clin Exp Rheumatol. (2017) 35:234–40.

PubMed Abstract | Google Scholar

173. Grant AJ, Goddard S, Ahmed-Choudhury J, Reynolds G, Jackson DG, Briskin M, et al. Hepatic expression of secondary lymphoid chemokine (Ccl21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol. (2002) 160:1445–55. doi: 10.1016/s0002-9440(10)62570-9

PubMed Abstract | Crossref Full Text | Google Scholar

174. Yang Z, Liu M, Chang Z, Du C, Yang Y, Zhang C, et al. Myeloid-derived growth factor promotes M2 macrophage polarization and attenuates sjögren's syndrome via suppression of the cx3cl1/cx3cr1 axis. Front Immunol. (2024) 15:1465938. doi: 10.3389/fimmu.2024.1465938

PubMed Abstract | Crossref Full Text | Google Scholar

175. Zhang W, Fei Y, Gao J, Liu B, and Zhang F. The role of cxcr3 in the induction of primary biliary cirrhosis. Clin Dev Immunol. (2011) 2011:564062. doi: 10.1155/2011/564062

PubMed Abstract | Crossref Full Text | Google Scholar

176. Han L and Zhang L. Ccl21/ccr7 axis as a therapeutic target for autoimmune diseases. Int Immunopharmacol. (2023) 121:110431. doi: 10.1016/j.intimp.2023.110431

PubMed Abstract | Crossref Full Text | Google Scholar

177. Ma X, Liu Z, Chang T, Yao C, Yang Y, Shang B, et al. Network meta-analysis of integrated traditional chinese and western medicine in the treatment of sjogren's syndrome. Front Pharmacol. (2024) 15:1455969. doi: 10.3389/fphar.2024.1455969

PubMed Abstract | Crossref Full Text | Google Scholar

178. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. (2009) 136:1281–7. doi: 10.1053/j.gastro.2009.01.003

PubMed Abstract | Crossref Full Text | Google Scholar

179. Liew SH, Nichols KK, Klamerus KJ, Li JZ, Zhang M, and Foulks GN. Tofacitinib (Cp-690,550), a janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology. (2012) 119:1328–35. doi: 10.1016/j.ophtha.2012.01.028

PubMed Abstract | Crossref Full Text | Google Scholar

180. Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, et al. An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs. J Hepatol. (2021) 75:572–81. doi: 10.1016/j.jhep.2021.04.055

PubMed Abstract | Crossref Full Text | Google Scholar

181. Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in sjögren's syndrome: A randomized, phase 2, double-blind, placebo-controlled study. Rheumatol (Oxford England). (2022) 61:4797–808. doi: 10.1093/rheumatology/keac167

PubMed Abstract | Crossref Full Text | Google Scholar

182. Bai W, Liu H, Dou L, Yang Y, Leng X, Li M, et al. Pilot study of baricitinib for active sjogren's syndrome. Ann rheumatic Dis. (2022) 81:1050–2. doi: 10.1136/annrheumdis-2021-222053

PubMed Abstract | Crossref Full Text | Google Scholar

183. Gordon SC, Trudeau S, Regev A, Uhas JM, Chakladar S, Pinto-Correia A, et al. Baricitinib and primary biliary cholangitis. J Trans Autoimmun. (2021) 4:100107. doi: 10.1016/j.jtauto.2021.100107

PubMed Abstract | Crossref Full Text | Google Scholar

184. Blokland SLM, Hillen MR, Wichers CGK, Zimmermann M, Kruize AA, Radstake T, et al. Increased mtorc1 activation in salivary gland B cells and T cells from patients with sjögren's syndrome: mtor inhibition as a novel therapeutic strategy to halt immunopathology? RMD Open. (2019) 5:e000701. doi: 10.1136/rmdopen-2018-000701

PubMed Abstract | Crossref Full Text | Google Scholar

185. Wu C, Zhang W, Luo Y, Cheng C, Wang X, Jiang Y, et al. Zebrafish ppp1r21 mutant as a model for the study of primary biliary cholangitis. J Genet Genomics = Yi Chuan xue bao. (2023) 50:1004–13. doi: 10.1016/j.jgg.2023.05.013

PubMed Abstract | Crossref Full Text | Google Scholar

186. Pu J, Wang X, Riaz F, Zhang T, Gao R, Pan S, et al. Effectiveness and safety of iguratimod in treating primary sjögren's syndrome: A systematic review and meta-analysis. Front Pharmacol. (2021) 12:621208. doi: 10.3389/fphar.2021.621208

PubMed Abstract | Crossref Full Text | Google Scholar

187. Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. Hepatol (Baltimore Md). (2016) 64:189–99. doi: 10.1002/hep.28359

PubMed Abstract | Crossref Full Text | Google Scholar

188. Chimenti MS, Talamonti M, Novelli L, Teoli M, Galluzzo M, Triggianese P, et al. Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and sjögren syndrome. Rep Two cases Rev Literature J Dermatol Case Rep. (2015) 9:71–5. doi: 10.3315/jdcr.2015.1207

PubMed Abstract | Crossref Full Text | Google Scholar

189. He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y, et al. Efficacy and safety of low-dose interleukin 2 for primary sjögren syndrome: A randomized clinical trial. JAMA network Open. (2022) 5:e2241451. doi: 10.1001/jamanetworkopen.2022.41451

PubMed Abstract | Crossref Full Text | Google Scholar

190. Arnold DD, Yalamanoglu A, and Boyman O. Systematic review of safety and efficacy of il-1-targeted biologics in treating immune-mediated disorders. Front Immunol. (2022) 13:888392. doi: 10.3389/fimmu.2022.888392

PubMed Abstract | Crossref Full Text | Google Scholar

191. Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, et al. Interleukin 6 receptor inhibition in primary sjögren syndrome: A multicentre double-blind randomised placebo-controlled trial. Ann rheumatic Dis. (2021) 80:329–38. doi: 10.1136/annrheumdis-2020-218467

PubMed Abstract | Crossref Full Text | Google Scholar

192. Guo X, Dang W, Li N, Wang Y, Sun D, Nian H, et al. Ppar-A Agonist fenofibrate ameliorates sjögren syndrome-like dacryoadenitis by modulating th1/th17 and treg cell responses in nod mice. Invest Ophthalmol Visual Sci. (2022) 63:12. doi: 10.1167/iovs.63.6.12

PubMed Abstract | Crossref Full Text | Google Scholar

193. Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, and Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. (2004) 10:894–8. doi: 10.3748/wjg.v10.i6.894

PubMed Abstract | Crossref Full Text | Google Scholar

194. Honda A, Tanaka A, Kaneko T, Komori A, Abe M, Inao M, et al. Bezafibrate improves globe and uk-pbc scores and long-term outcomes in patients with primary biliary cholangitis. Hepatol (Baltimore Md). (2019) 70:2035–46. doi: 10.1002/hep.30552

PubMed Abstract | Crossref Full Text | Google Scholar

195. Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. New Engl J Med. (2024) 390:783–94. doi: 10.1056/NEJMoa2312100

PubMed Abstract | Crossref Full Text | Google Scholar

196. Kremer AE, Mayo MJ, Hirschfield G, Levy C, Bowlus CL, Jones DE, et al. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver international: Off J Int Assoc Study Liver. (2022) 42:112–23. doi: 10.1111/liv.15039

PubMed Abstract | Crossref Full Text | Google Scholar

197. Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to udca. J Hepatol. (2021) 74:1344–54. doi: 10.1016/j.jhep.2021.01.013

PubMed Abstract | Crossref Full Text | Google Scholar

198. Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. New Engl J Med. (2024) 390:795–805. doi: 10.1056/NEJMoa2306185

PubMed Abstract | Crossref Full Text | Google Scholar

199. Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, et al. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. (2022) 76:75–85. doi: 10.1016/j.jhep.2021.08.025

PubMed Abstract | Crossref Full Text | Google Scholar

200. Verstappen GM, Meiners PM, Corneth OBJ, Visser A, Arends S, Abdulahad WH, et al. Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary sjögren's syndrome. Arthritis Rheumatol (Hoboken NJ). (2017) 69:1850–61. doi: 10.1002/art.40165

PubMed Abstract | Crossref Full Text | Google Scholar

201. Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, et al. Efficacy and safety of abatacept in active primary sjögren's syndrome: results of a phase iii, randomised, placebo-controlled trial. Ann rheumatic Dis. (2021) 80:339–48. doi: 10.1136/annrheumdis-2020-218599

PubMed Abstract | Crossref Full Text | Google Scholar

202. Popp F, Semela D, von Kempis J, and Mueller RB. Improvement of primary biliary cholangitis (Pbc) under treatment with sulfasalazine and abatacept. BMJ Case Rep. (2018) 2018. doi: 10.1136/bcr-2018-224205

PubMed Abstract | Crossref Full Text | Google Scholar

203. De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. Efficacy and safety of belimumab given for 12 months in primary sjögren's syndrome: the beliss open-label phase ii study. Rheumatol (Oxford England). (2015) 54:2249–56. doi: 10.1093/rheumatology/kev257

PubMed Abstract | Crossref Full Text | Google Scholar

204. Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary sjögren's syndrome: results of the beliss open-label phase ii study. Ann rheumatic Dis. (2015) 74:526–31. doi: 10.1136/annrheumdis-2013-203991

PubMed Abstract | Crossref Full Text | Google Scholar

205. Kolev M, Sarbu AC, Möller B, Maurer B, Kollert F, and Semmo N. Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series. J Trans Autoimmun. (2023) 6:100189. doi: 10.1016/j.jtauto.2023.100189

PubMed Abstract | Crossref Full Text | Google Scholar

206. Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, et al. Safety and efficacy of subcutaneous ianalumab (Vay736) in patients with primary sjögren's syndrome: A randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet (London England). (2022) 399:161–71. doi: 10.1016/s0140-6736(21)02251-0

PubMed Abstract | Crossref Full Text | Google Scholar

207. Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, et al. Efficacy and safety of remibrutinib, a selective potent oral btk inhibitor, in sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann rheumatic Dis. (2024) 83:360–71. doi: 10.1136/ard-2023-224691

PubMed Abstract | Crossref Full Text | Google Scholar

208. Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L, et al. Efficacy and safety of telitacicept in primary sjögren's syndrome: A randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatol (Oxford England). (2024) 63:698–705. doi: 10.1093/rheumatology/kead265

PubMed Abstract | Crossref Full Text | Google Scholar

209. St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, et al. Cd40 ligand antagonist dazodalibep in sjögren's disease: A randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. (2024) 30:1583–92. doi: 10.1038/s41591-024-03009-3

PubMed Abstract | Crossref Full Text | Google Scholar

210. Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, et al. Safety and efficacy of subcutaneous iscalimab (Cfz533) in two distinct populations of patients with sjögren's disease (Twinss): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet (London England). (2024) 404:540–53. doi: 10.1016/s0140-6736(24)01211-x

PubMed Abstract | Crossref Full Text | Google Scholar

211. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary sjögren syndrome with rituximab: A randomized trial. Ann Internal Med. (2014) 160:233–42. doi: 10.7326/m13-1085

PubMed Abstract | Crossref Full Text | Google Scholar

212. Khanna A, Jopson L, Howel D, Bryant A, Blamire A, Newton JL, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: A phase 2 randomized controlled trial. Hepatol (Baltimore Md). (2019) 70:1646–57. doi: 10.1002/hep.30099

PubMed Abstract | Crossref Full Text | Google Scholar

213. Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, Wakabayashi K, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatol (Baltimore Md). (2012) 55:512–21. doi: 10.1002/hep.24748

PubMed Abstract | Crossref Full Text | Google Scholar

214. Myers RP, Swain MG, Lee SS, Shaheen AA, and Burak KW. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. (2013) 108:933–41. doi: 10.1038/ajg.2013.51

PubMed Abstract | Crossref Full Text | Google Scholar

215. Zeng P, Jiang Z, Huang Z, Huang Y, Xu H, Chen C, et al. Pi3k/akt/mtor signaling pathway is downregulated by runzaoling (Rzl) in sjögren's syndrome. Mediators Inflammation. (2022) 2022:7236118. doi: 10.1155/2022/7236118

PubMed Abstract | Crossref Full Text | Google Scholar

216. Wang Y, Feng R, Cheng G, Huang B, Tian J, Gan Y, et al. Low dose interleukin-2 ameliorates sjögren's syndrome in a murine model. Front Med. (2022) 9:887354. doi: 10.3389/fmed.2022.887354

PubMed Abstract | Crossref Full Text | Google Scholar

217. Wang Z, Liu Z, Zheng J, Huang L, Jin R, Wang X, et al. The effects of low-dose il-2 on th17/treg cell imbalance in primary biliary cholangitis mouse models. BMC Gastroenterol. (2024) 24:87. doi: 10.1186/s12876-024-03176-0

PubMed Abstract | Crossref Full Text | Google Scholar

218. Zhang MA, Rego D, Moshkova M, Kebir H, Chruscinski A, Nguyen H, et al. Peroxisome proliferator-activated receptor (Ppar)A and -Γ Regulate ifnγ and il-17a production by human T cells in a sex-specific way. Proc Natl Acad Sci United States America. (2012) 109:9505–10. doi: 10.1073/pnas.1118458109

PubMed Abstract | Crossref Full Text | Google Scholar

219. Ding D, Guo G, Liu Y, Zheng L, Jia G, Deng J, et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatol Commun. (2022) 6:3487–95. doi: 10.1002/hep4.2103

PubMed Abstract | Crossref Full Text | Google Scholar

220. Levy C, Peter JA, Nelson DR, Keach J, Petz J, Cabrera R, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Alimentary Pharmacol Ther. (2011) 33:235–42. doi: 10.1111/j.1365-2036.2010.04512.x

PubMed Abstract | Crossref Full Text | Google Scholar

221. Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi H, Ebe H, et al. Effectiveness of abatacept for patients with sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: rose (Rheumatoid arthritis with orencia trial toward sjögren's syndrome endocrinopathy) trial. Modern Rheumatol. (2016) 26:891–9. doi: 10.3109/14397595.2016.1158773

PubMed Abstract | Crossref Full Text | Google Scholar

222. de Wolff L, van Nimwegen JF, Mossel E, van Zuiden GS, Stel AJ, Majoor KI, et al. Long-term abatacept treatment for 48 weeks in patients with primary sjögren's syndrome: the open-label extension phase of the asap-iii trial. Semin Arthritis rheumatism. (2022) 53:151955. doi: 10.1016/j.semarthrit.2022.151955

PubMed Abstract | Crossref Full Text | Google Scholar

223. Onuora S. Abatacept no better than placebo for pss. Nat Rev Rheumatol. (2020) 16:186. doi: 10.1038/s41584-020-0390-8

PubMed Abstract | Crossref Full Text | Google Scholar

224. Dhirapong A, Yang GX, Nadler S, Zhang W, Tsuneyama K, Leung P, et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatol (Baltimore Md). (2013) 57:708–15. doi: 10.1002/hep.26067

PubMed Abstract | Crossref Full Text | Google Scholar

225. Bowlus CL, Yang GX, Liu CH, Johnson CR, Dhaliwal SS, Frank D, et al. Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature. J Autoimmun. (2019) 101:26–34. doi: 10.1016/j.jaut.2019.04.005

PubMed Abstract | Crossref Full Text | Google Scholar

226. Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary sjögren's syndrome: A prospective, multi-center, follow-up study. Arthritis Res Ther. (2013) 15:R172. doi: 10.1186/ar4359

PubMed Abstract | Crossref Full Text | Google Scholar

227. Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary sjögren's syndrome after B cell depletion therapy. Ann rheumatic Dis. (2012) 71:1881–7. doi: 10.1136/annrheumdis-2011-201189

PubMed Abstract | Crossref Full Text | Google Scholar

228. Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, et al. A randomized, phase ii study of sequential belimumab and rituximab in primary sjögren's syndrome. JCI Insight. (2022) 7. doi: 10.1172/jci.insight.163030

PubMed Abstract | Crossref Full Text | Google Scholar

229. Zhang W, Shao T, Leung PSC, Tsuneyama K, Heuer L, Young HA, et al. Dual B-cell targeting therapy ameliorates autoimmune cholangitis. J Autoimmun. (2022) 132:102897. doi: 10.1016/j.jaut.2022.102897

PubMed Abstract | Crossref Full Text | Google Scholar